1
|
Mitchell W, Goeminne LJE, Tyshkovskiy A, Zhang S, Chen JY, Paulo JA, Pierce KA, Choy AH, Clish CB, Gygi SP, Gladyshev VN. Multi-omics characterization of partial chemical reprogramming reveals evidence of cell rejuvenation. eLife 2024; 12:RP90579. [PMID: 38517750 PMCID: PMC10959535 DOI: 10.7554/elife.90579] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/24/2024] Open
Abstract
Partial reprogramming by cyclic short-term expression of Yamanaka factors holds promise for shifting cells to younger states and consequently delaying the onset of many diseases of aging. However, the delivery of transgenes and potential risk of teratoma formation present challenges for in vivo applications. Recent advances include the use of cocktails of compounds to reprogram somatic cells, but the characteristics and mechanisms of partial cellular reprogramming by chemicals remain unclear. Here, we report a multi-omics characterization of partial chemical reprogramming in fibroblasts from young and aged mice. We measured the effects of partial chemical reprogramming on the epigenome, transcriptome, proteome, phosphoproteome, and metabolome. At the transcriptome, proteome, and phosphoproteome levels, we saw widescale changes induced by this treatment, with the most notable signature being an upregulation of mitochondrial oxidative phosphorylation. Furthermore, at the metabolome level, we observed a reduction in the accumulation of aging-related metabolites. Using both transcriptomic and epigenetic clock-based analyses, we show that partial chemical reprogramming reduces the biological age of mouse fibroblasts. We demonstrate that these changes have functional impacts, as evidenced by changes in cellular respiration and mitochondrial membrane potential. Taken together, these results illuminate the potential for chemical reprogramming reagents to rejuvenate aged biological systems and warrant further investigation into adapting these approaches for in vivo age reversal.
Collapse
Affiliation(s)
- Wayne Mitchell
- Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical SchoolBostonUnited States
| | - Ludger JE Goeminne
- Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical SchoolBostonUnited States
| | - Alexander Tyshkovskiy
- Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical SchoolBostonUnited States
| | - Sirui Zhang
- Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical SchoolBostonUnited States
| | - Julie Y Chen
- Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical SchoolBostonUnited States
| | - Joao A Paulo
- Department of Cell Biology, Harvard Medical SchoolBostonUnited States
| | - Kerry A Pierce
- Broad Institute of MIT and HarvardCambridgeUnited States
| | | | - Clary B Clish
- Broad Institute of MIT and HarvardCambridgeUnited States
| | - Steven P Gygi
- Department of Cell Biology, Harvard Medical SchoolBostonUnited States
| | - Vadim N Gladyshev
- Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical SchoolBostonUnited States
| |
Collapse
|
2
|
Mitchell W, Goeminne LJ, Tyshkovskiy A, Zhang S, Chen JY, Paulo JA, Pierce KA, Choy AH, Clish CB, Gygi SP, Gladyshev VN. Multi-omics characterization of partial chemical reprogramming reveals evidence of cell rejuvenation. bioRxiv 2023:2023.06.30.546730. [PMID: 37425825 PMCID: PMC10327104 DOI: 10.1101/2023.06.30.546730] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 07/11/2023]
Abstract
Partial reprogramming by cyclic short-term expression of Yamanaka factors holds promise for shifting cells to younger states and consequently delaying the onset of many diseases of aging. However, the delivery of transgenes and potential risk of teratoma formation present challenges for in vivo applications. Recent advances include the use of cocktails of compounds to reprogram somatic cells, but the characteristics and mechanisms of partial cellular reprogramming by chemicals remain unclear. Here, we report a multi-omics characterization of partial chemical reprogramming in fibroblasts from young and aged mice. We measured the effects of partial chemical reprogramming on the epigenome, transcriptome, proteome, phosphoproteome, and metabolome. At the transcriptome, proteome, and phosphoproteome levels, we saw widescale changes induced by this treatment, with the most notable signature being an upregulation of mitochondrial oxidative phosphorylation. Furthermore, at the metabolome level, we observed a reduction in the accumulation of aging-related metabolites. Using both transcriptomic and epigenetic clock-based analyses, we show that partial chemical reprogramming reduces the biological age of mouse fibroblasts. We demonstrate that these changes have functional impacts, as evidenced by changes in cellular respiration and mitochondrial membrane potential. Taken together, these results illuminate the potential for chemical reprogramming reagents to rejuvenate aged biological systems and warrant further investigation into adapting these approaches for in vivo age reversal.
Collapse
Affiliation(s)
- Wayne Mitchell
- Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 United States
| | - Ludger J.E. Goeminne
- Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 United States
| | - Alexander Tyshkovskiy
- Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 United States
| | - Sirui Zhang
- Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 United States
| | - Julie Y. Chen
- Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 United States
| | - Joao A. Paulo
- Department of Cell Biology, Harvard Medical School, Boston, MA 02115 United States
| | - Kerry A. Pierce
- Broad Institute of MIT and Harvard, Cambridge, MA 01241 United States
| | - Angelina H. Choy
- Broad Institute of MIT and Harvard, Cambridge, MA 01241 United States
| | - Clary B. Clish
- Broad Institute of MIT and Harvard, Cambridge, MA 01241 United States
| | - Steven P. Gygi
- Department of Cell Biology, Harvard Medical School, Boston, MA 02115 United States
| | - Vadim N. Gladyshev
- Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA 02115 United States
| |
Collapse
|
3
|
Gopal RK, Vantaku VR, Panda A, Reimer B, Rath S, To TL, Fisch AS, Cetinbas M, Livneh M, Calcaterra MJ, Gigliotti BJ, Pierce KA, Clish CB, Dias-Santagata D, Sadow PM, Wirth LJ, Daniels GH, Sadreyev RI, Calvo SE, Parangi S, Mootha VK. Effectors Enabling Adaptation to Mitochondrial Complex I Loss in Hürthle Cell Carcinoma. Cancer Discov 2023; 13:1904-1921. [PMID: 37262067 PMCID: PMC10401073 DOI: 10.1158/2159-8290.cd-22-0976] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2022] [Revised: 04/05/2023] [Accepted: 05/30/2023] [Indexed: 06/03/2023]
Abstract
Oncocytic (Hürthle cell) carcinoma of the thyroid (HCC) is genetically characterized by complex I mitochondrial DNA mutations and widespread chromosomal losses. Here, we utilize RNA sequencing and metabolomics to identify candidate molecular effectors activated by these genetic drivers. We find glutathione biosynthesis, amino acid metabolism, mitochondrial unfolded protein response, and lipid peroxide scavenging to be increased in HCC. A CRISPR-Cas9 knockout screen in a new HCC model reveals which pathways are key for fitness, and highlights loss of GPX4, a defense against lipid peroxides and ferroptosis, as a strong liability. Rescuing complex I redox activity with the yeast NADH dehydrogenase (NDI1) in HCC cells diminishes ferroptosis sensitivity, while inhibiting complex I in normal thyroid cells augments ferroptosis induction. Our work demonstrates unmitigated lipid peroxide stress to be an HCC vulnerability that is mechanistically coupled to the genetic loss of mitochondrial complex I activity. SIGNIFICANCE HCC harbors abundant mitochondria, mitochondrial DNA mutations, and chromosomal losses. Using a CRISPR-Cas9 screen inspired by transcriptomic and metabolomic profiling, we identify molecular effectors essential for cell fitness. We uncover lipid peroxide stress as a vulnerability coupled to mitochondrial complex I loss in HCC. See related article by Frank et al., p. 1884. This article is highlighted in the In This Issue feature, p. 1749.
Collapse
Affiliation(s)
- Raj K. Gopal
- Howard Hughes Medical Institute and Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts
- Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
- Cancer Center, Massachusetts General Hospital, Boston, Massachusetts
- Harvard Medical School, Boston, Massachusetts
| | - Venkata R. Vantaku
- Harvard Medical School, Boston, Massachusetts
- Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts
| | - Apekshya Panda
- Howard Hughes Medical Institute and Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts
| | - Bryn Reimer
- Howard Hughes Medical Institute and Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts
| | - Sneha Rath
- Howard Hughes Medical Institute and Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts
| | - Tsz-Leung To
- Howard Hughes Medical Institute and Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts
| | - Adam S. Fisch
- Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts
| | - Murat Cetinbas
- Howard Hughes Medical Institute and Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts
- Harvard Medical School, Boston, Massachusetts
| | - Maia Livneh
- Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts
| | | | | | - Kerry A. Pierce
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts
| | - Clary B. Clish
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts
| | - Dora Dias-Santagata
- Harvard Medical School, Boston, Massachusetts
- Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts
| | - Peter M. Sadow
- Cancer Center, Massachusetts General Hospital, Boston, Massachusetts
- Harvard Medical School, Boston, Massachusetts
- Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts
| | - Lori J. Wirth
- Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
- Cancer Center, Massachusetts General Hospital, Boston, Massachusetts
- Harvard Medical School, Boston, Massachusetts
| | - Gilbert H. Daniels
- Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
- Cancer Center, Massachusetts General Hospital, Boston, Massachusetts
- Harvard Medical School, Boston, Massachusetts
- Thyroid Unit, Massachusetts General Hospital, Boston, Massachusetts
| | - Ruslan I. Sadreyev
- Howard Hughes Medical Institute and Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts
- Harvard Medical School, Boston, Massachusetts
- Department of Pathology, Massachusetts General Hospital, Boston, Massachusetts
| | - Sarah E. Calvo
- Howard Hughes Medical Institute and Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts
| | - Sareh Parangi
- Cancer Center, Massachusetts General Hospital, Boston, Massachusetts
- Harvard Medical School, Boston, Massachusetts
- Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts
| | - Vamsi K. Mootha
- Howard Hughes Medical Institute and Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts
- Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
- Department of Systems Biology, Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
4
|
Zhou W, Simic P, Zhou IY, Caravan P, Vela Parada X, Wen D, Washington OL, Shvedova M, Pierce KA, Clish CB, Mannstadt M, Kobayashi T, Wein MN, Jüppner H, Rhee EP. Kidney glycolysis serves as a mammalian phosphate sensor that maintains phosphate homeostasis. J Clin Invest 2023; 133:e164610. [PMID: 36821389 PMCID: PMC10104895 DOI: 10.1172/jci164610] [Citation(s) in RCA: 18] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Accepted: 02/21/2023] [Indexed: 02/24/2023] Open
Abstract
How phosphate levels are detected in mammals is unknown. The bone-derived hormone fibroblast growth factor 23 (FGF23) lowers blood phosphate levels by reducing kidney phosphate reabsorption and 1,25(OH)2D production, but phosphate does not directly stimulate bone FGF23 expression. Using PET scanning and LC-MS, we found that phosphate increases kidney-specific glycolysis and synthesis of glycerol-3-phosphate (G-3-P), which then circulates to bone to trigger FGF23 production. Further, we found that G-3-P dehydrogenase 1 (Gpd1), a cytosolic enzyme that synthesizes G-3-P and oxidizes NADH to NAD+, is required for phosphate-stimulated G-3-P and FGF23 production and prevention of hyperphosphatemia. In proximal tubule cells, we found that phosphate availability is substrate-limiting for glycolysis and G-3-P production and that increased glycolysis and Gpd1 activity are coupled through cytosolic NAD+ recycling. Finally, we show that the type II sodium-dependent phosphate cotransporter Npt2a, which is primarily expressed in the proximal tubule, conferred kidney specificity to phosphate-stimulated G-3-P production. Importantly, exogenous G-3-P stimulated FGF23 production when Npt2a or Gpd1 were absent, confirming that it was the key circulating factor downstream of glycolytic phosphate sensing in the kidney. Together, these findings place glycolysis at the nexus of mineral and energy metabolism and identify a kidney-bone feedback loop that controls phosphate homeostasis.
Collapse
Affiliation(s)
- Wen Zhou
- Nephrology Division, Department of Medicine, and
- Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Petra Simic
- Nephrology Division, Department of Medicine, and
- Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Iris Y. Zhou
- Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, Massachusetts, USA
| | - Peter Caravan
- Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, Massachusetts, USA
| | - Xavier Vela Parada
- Nephrology Division, Department of Medicine, and
- Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Donghai Wen
- Nephrology Division, Department of Medicine, and
- Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Onica L. Washington
- Nephrology Division, Department of Medicine, and
- Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Maria Shvedova
- Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Kerry A. Pierce
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
| | - Clary B. Clish
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
| | - Michael Mannstadt
- Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Tatsuya Kobayashi
- Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Marc N. Wein
- Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Harald Jüppner
- Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
- Pediatric Nephrology Unit, Department of Pediatrics, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Eugene P. Rhee
- Nephrology Division, Department of Medicine, and
- Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| |
Collapse
|
5
|
Rojas-Tapias DF, Brown EM, Temple ER, Onyekaba MA, Mohamed AMT, Duncan K, Schirmer M, Walker RL, Mayassi T, Pierce KA, Ávila-Pacheco J, Clish CB, Vlamakis H, Xavier RJ. Inflammation-associated nitrate facilitates ectopic colonization of oral bacterium Veillonella parvula in the intestine. Nat Microbiol 2022; 7:1673-1685. [PMID: 36138166 PMCID: PMC9728153 DOI: 10.1038/s41564-022-01224-7] [Citation(s) in RCA: 25] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/18/2021] [Accepted: 08/03/2022] [Indexed: 12/13/2022]
Abstract
Colonization of the intestine by oral microbes has been linked to multiple diseases such as inflammatory bowel disease and colon cancer, yet mechanisms allowing expansion in this niche remain largely unknown. Veillonella parvula, an asaccharolytic, anaerobic, oral microbe that derives energy from organic acids, increases in abundance in the intestine of patients with inflammatory bowel disease. Here we show that nitrate, a signature metabolite of inflammation, allows V. parvula to transition from fermentation to anaerobic respiration. Nitrate respiration, through the narGHJI operon, boosted Veillonella growth on organic acids and also modulated its metabolic repertoire, allowing it to use amino acids and peptides as carbon sources. This metabolic shift was accompanied by changes in carbon metabolism and ATP production pathways. Nitrate respiration was fundamental for ectopic colonization in a mouse model of colitis, because a V. parvula narG deletion mutant colonized significantly less than a wild-type strain during inflammation. These results suggest that V. parvula harness conditions present during inflammation to colonize in the intestine.
Collapse
Affiliation(s)
- Daniel F Rojas-Tapias
- Broad Institute of MIT and Harvard, Cambridge, MA, USA.,Center for Computational and Integrative Biology and Department of Molecular Biology, Massachusetts General Hospital, Boston, MA, USA.,Department of Agricultural Microbiology, Colombian Corporation for Agricultural Research-Agrosavia, Bogotá, Colombia
| | - Eric M Brown
- Broad Institute of MIT and Harvard, Cambridge, MA, USA.,Center for Computational and Integrative Biology and Department of Molecular Biology, Massachusetts General Hospital, Boston, MA, USA
| | | | | | - Ahmed M T Mohamed
- Broad Institute of MIT and Harvard, Cambridge, MA, USA.,Center for Computational and Integrative Biology and Department of Molecular Biology, Massachusetts General Hospital, Boston, MA, USA
| | - Kellyanne Duncan
- Broad Institute of MIT and Harvard, Cambridge, MA, USA.,Center for Computational and Integrative Biology and Department of Molecular Biology, Massachusetts General Hospital, Boston, MA, USA
| | - Melanie Schirmer
- Broad Institute of MIT and Harvard, Cambridge, MA, USA.,Emmy Noether Group, ZIEL-Institute for Food and Health, Technical University of Munich, Freising, Germany
| | | | - Toufic Mayassi
- Broad Institute of MIT and Harvard, Cambridge, MA, USA.,Center for Computational and Integrative Biology and Department of Molecular Biology, Massachusetts General Hospital, Boston, MA, USA
| | - Kerry A Pierce
- Metabolomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | | | - Clary B Clish
- Metabolomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Hera Vlamakis
- Broad Institute of MIT and Harvard, Cambridge, MA, USA.,Center for Microbiome Informatics and Therapeutics, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Ramnik J Xavier
- Broad Institute of MIT and Harvard, Cambridge, MA, USA. .,Center for Computational and Integrative Biology and Department of Molecular Biology, Massachusetts General Hospital, Boston, MA, USA. .,Center for Microbiome Informatics and Therapeutics, Massachusetts Institute of Technology, Cambridge, MA, USA.
| |
Collapse
|
6
|
Heckel E, Cagnone G, Agnihotri T, Cakir B, Das A, Kim JS, Kim N, Lavoie G, Situ A, Pundir S, Sun Y, Wünnemann F, Pierce KA, Dennis C, Mitchell GA, Chemtob S, Rezende FA, Andelfinger G, Clish CB, Roux PP, Sapieha P, Smith LE, Joyal JS. Triglyceride-derived fatty acids reduce autophagy in a model of retinal angiomatous proliferation. JCI Insight 2022; 7:e154174. [PMID: 35167498 PMCID: PMC8986067 DOI: 10.1172/jci.insight.154174] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2021] [Accepted: 02/09/2022] [Indexed: 11/17/2022] Open
Abstract
Dyslipidemia and autophagy have been implicated in the pathogenesis of blinding neovascular age-related macular degeneration (NV-AMD). VLDL receptor (VLDLR), expressed in photoreceptors with a high metabolic rate, facilitates the uptake of triglyceride-derived fatty acids. Since fatty acid uptake is reduced in Vldlr-/- tissues, more remain in circulation, and the retina is fuel deficient, driving the formation in mice of neovascular lesions reminiscent of retinal angiomatous proliferation (RAP), a subtype of NV-AMD. Nutrient scarcity and energy failure are classically mitigated by increasing autophagy. We found that excess circulating lipids restrained retinal autophagy, which contributed to pathological angiogenesis in the Vldlr-/- RAP model. Triglyceride-derived fatty acid sensed by free fatty acid receptor 1 (FFAR1) restricted autophagy and oxidative metabolism in photoreceptors. FFAR1 suppressed transcription factor EB (TFEB), a master regulator of autophagy and lipid metabolism. Reduced TFEB, in turn, decreased sirtuin-3 expression and mitochondrial respiration. Metabolomic signatures of mouse RAP-like retinas were consistent with a role in promoting angiogenesis. This signature was also found in human NV-AMD vitreous. Restoring photoreceptor autophagy in Vldlr-/- retinas, either pharmacologically or by deleting Ffar1, enhanced metabolic efficiency and suppressed pathological angiogenesis. Dysregulated autophagy by circulating lipids might therefore contribute to the energy failure of photoreceptors driving neovascular eye diseases, and FFAR1 may be a target for intervention.
Collapse
Affiliation(s)
- Emilie Heckel
- Department of Pharmacology, University of Montreal, Montreal, Quebec, Canada
| | - Gael Cagnone
- Department of Pharmacology, University of Montreal, Montreal, Quebec, Canada
| | - Tapan Agnihotri
- Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada
| | - Bertan Cakir
- Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Ashim Das
- Department of Pharmacology, University of Montreal, Montreal, Quebec, Canada
| | - Jin Sung Kim
- Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada
| | - Nicholas Kim
- Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada
| | - Geneviève Lavoie
- Department of Pathology and Cell Biology, Institute for Research in Immunology and Cancer (IRIC), and
| | - Anu Situ
- Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada
| | - Sheetal Pundir
- Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada
| | - Ye Sun
- Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Florian Wünnemann
- Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada
| | - Kerry A. Pierce
- Metabolomics Platform, Broad Institute of MIT and Harvard University, Cambridge, Massachusetts, USA
| | - Courtney Dennis
- Metabolomics Platform, Broad Institute of MIT and Harvard University, Cambridge, Massachusetts, USA
| | - Grant A. Mitchell
- Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada
| | - Sylvain Chemtob
- Department of Pharmacology, University of Montreal, Montreal, Quebec, Canada
- Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada
- Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada
- Department of Ophthalmology, University of Montreal, Montreal, Quebec, Canada
| | - Flavio A. Rezende
- Department of Ophthalmology, University of Montreal, Montreal, Quebec, Canada
| | - Gregor Andelfinger
- Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada
| | - Clary B. Clish
- Metabolomics Platform, Broad Institute of MIT and Harvard University, Cambridge, Massachusetts, USA
| | - Philippe P. Roux
- Department of Pathology and Cell Biology, Institute for Research in Immunology and Cancer (IRIC), and
| | - Przemyslaw Sapieha
- Department of Ophthalmology, University of Montreal, Montreal, Quebec, Canada
| | - Lois E.H. Smith
- Department of Ophthalmology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA
| | - Jean-Sébastien Joyal
- Department of Pharmacology, University of Montreal, Montreal, Quebec, Canada
- Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada
- Department of Pediatrics, University of Montreal, Montreal, Quebec, Canada
- Department of Ophthalmology, University of Montreal, Montreal, Quebec, Canada
| |
Collapse
|
7
|
Oren Y, Tsabar M, Cuoco MS, Amir-Zilberstein L, Cabanos HF, Hütter JC, Hu B, Thakore PI, Tabaka M, Fulco CP, Colgan W, Cuevas BM, Hurvitz SA, Slamon DJ, Deik A, Pierce KA, Clish C, Hata AN, Zaganjor E, Lahav G, Politi K, Brugge JS, Regev A. Cycling cancer persister cells arise from lineages with distinct programs. Nature 2021; 596:576-582. [PMID: 34381210 PMCID: PMC9209846 DOI: 10.1038/s41586-021-03796-6] [Citation(s) in RCA: 194] [Impact Index Per Article: 64.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2020] [Accepted: 07/02/2021] [Indexed: 02/07/2023]
Abstract
Non-genetic mechanisms have recently emerged as important drivers of cancer therapy failure1, where some cancer cells can enter a reversible drug-tolerant persister state in response to treatment2. Although most cancer persisters remain arrested in the presence of the drug, a rare subset can re-enter the cell cycle under constitutive drug treatment. Little is known about the non-genetic mechanisms that enable cancer persisters to maintain proliferative capacity in the presence of drugs. To study this rare, transiently resistant, proliferative persister population, we developed Watermelon, a high-complexity expressed barcode lentiviral library for simultaneous tracing of each cell's clonal origin and proliferative and transcriptional states. Here we show that cycling and non-cycling persisters arise from different cell lineages with distinct transcriptional and metabolic programs. Upregulation of antioxidant gene programs and a metabolic shift to fatty acid oxidation are associated with persister proliferative capacity across multiple cancer types. Impeding oxidative stress or metabolic reprogramming alters the fraction of cycling persisters. In human tumours, programs associated with cycling persisters are induced in minimal residual disease in response to multiple targeted therapies. The Watermelon system enabled the identification of rare persister lineages that are preferentially poised to proliferate under drug pressure, thus exposing new vulnerabilities that can be targeted to delay or even prevent disease recurrence.
Collapse
Affiliation(s)
- Yaara Oren
- Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA,Department of Cell Biology, Harvard Medical School, 240 Longwood Ave., Boston, MA, USA
| | - Michael Tsabar
- Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA,Department of Systems Biology, Harvard Medical School, Boston, MA, USA,Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, USA
| | - Michael S. Cuoco
- Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | | | - Heidie F. Cabanos
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA,Departments of Medicine, Harvard Medical School, Boston, MA, USA
| | - Jan-Christian Hütter
- Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Bomiao Hu
- Department of Pathology, Yale School of Medicine, New Haven, CT, USA
| | - Pratiksha I. Thakore
- Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA,Current address: Genentech, South San Francisco, CA, USA
| | - Marcin Tabaka
- Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Charles P Fulco
- Broad Institute of MIT and Harvard, Cambridge, MA, USA,Current address: Bristol Myers Squibb, Cambridge, MA, USA
| | | | - Brandon M. Cuevas
- Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA
| | - Sara A. Hurvitz
- David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA
| | - Dennis J. Slamon
- David Geffen School of Medicine, University of California, Los Angeles, Jonsson Comprehensive Cancer Center, Los Angeles, CA, USA
| | - Amy Deik
- Metabolomics Platform, Broad Institute, Cambridge, MA, USA
| | | | - Clary Clish
- Metabolomics Platform, Broad Institute, Cambridge, MA, USA
| | - Aaron N. Hata
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA,Departments of Medicine, Harvard Medical School, Boston, MA, USA
| | - Elma Zaganjor
- Department of Molecular Physiology and Biophysics, Vanderbilt University, Nashville, TN, USA
| | - Galit Lahav
- Department of Systems Biology, Harvard Medical School, Boston, MA, USA
| | - Katerina Politi
- Departments of Pathology (Section of Medical Oncology), Yale School of Medicine and Yale Cancer Center, New Haven, CT, USA
| | - Joan S. Brugge
- Department of Cell Biology, Harvard Medical School, 240 Longwood Ave., Boston, MA, USA,Ludwig Center at Harvard
| | - Aviv Regev
- Klarman Cell Observatory, Broad Institute of MIT and Harvard, Cambridge, MA, USA. .,Department of Biology, Massachusetts Institute of Technology, Cambridge, MA, USA. .,Howard Hughes Medical Institute, Chevy Chase, MD, USA. .,Genentech, South San Francisco, CA, USA.
| |
Collapse
|
8
|
Madison JM, Duong K, Vieux EF, Udeshi ND, Iqbal S, Requadt E, Fereshetian S, Lewis MC, Gomes AS, Pierce KA, Platt RJ, Zhang F, Campbell AJ, Lal D, Wagner FF, Clish CB, Carr SA, Sheng M, Scolnick EM, Cottrell JR. Regulation of purine metabolism connects KCTD13 to a metabolic disorder with autistic features. iScience 2020; 24:101935. [PMID: 33409479 PMCID: PMC7773955 DOI: 10.1016/j.isci.2020.101935] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2020] [Revised: 10/30/2020] [Accepted: 12/08/2020] [Indexed: 12/14/2022] Open
Abstract
Genetic variation of the 16p11.2 deletion locus containing the KCTD13 gene and of CUL3 is linked with autism. This genetic connection suggested that substrates of a CUL3-KCTD13 ubiquitin ligase may be involved in disease pathogenesis. Comparison of Kctd13 mutant (Kctd13 -/- ) and wild-type neuronal ubiquitylomes identified adenylosuccinate synthetase (ADSS), an enzyme that catalyzes the first step in adenosine monophosphate (AMP) synthesis, as a KCTD13 ligase substrate. In Kctd13 -/- neurons, there were increased levels of succinyl-adenosine (S-Ado), a metabolite downstream of ADSS. Notably, S-Ado levels are elevated in adenylosuccinate lyase deficiency, a metabolic disorder with autism and epilepsy phenotypes. The increased S-Ado levels in Kctd13 -/- neurons were decreased by treatment with an ADSS inhibitor. Lastly, functional analysis of human KCTD13 variants suggests that KCTD13 variation may alter ubiquitination of ADSS. These data suggest that succinyl-AMP metabolites accumulate in Kctd13 -/- neurons, and this observation may have implications for our understanding of 16p11.2 deletion syndrome.
Collapse
Affiliation(s)
- Jon M Madison
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| | - Karen Duong
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| | - Ellen F Vieux
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| | - Namrata D Udeshi
- Proteomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| | - Sumaiya Iqbal
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.,Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| | - Elise Requadt
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| | - Shaunt Fereshetian
- Proteomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| | - Michael C Lewis
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| | - Antonio S Gomes
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| | - Kerry A Pierce
- Metabolomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| | - Randall J Platt
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.,McGovern Institute, Massachusetts Institute of Technology, Cambridge, MA 02142, USA
| | - Feng Zhang
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.,McGovern Institute, Massachusetts Institute of Technology, Cambridge, MA 02142, USA
| | - Arthur J Campbell
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.,Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| | - Dennis Lal
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.,Lerner Research Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
| | - Florence F Wagner
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.,Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| | - Clary B Clish
- Metabolomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| | - Steven A Carr
- Proteomics Platform, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| | - Morgan Sheng
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| | - Edward M Scolnick
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| | - Jeffrey R Cottrell
- Stanley Center for Psychiatric Research, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| |
Collapse
|
9
|
Nayor M, Shah RV, Miller PE, Blodgett JB, Tanguay M, Pico AR, Murthy VL, Malhotra R, Houstis NE, Deik A, Pierce KA, Bullock K, Dailey L, Velagaleti RS, Moore SA, Ho JE, Baggish AL, Clish CB, Larson MG, Vasan RS, Lewis GD. Metabolic Architecture of Acute Exercise Response in Middle-Aged Adults in the Community. Circulation 2020; 142:1905-1924. [PMID: 32927962 PMCID: PMC8049528 DOI: 10.1161/circulationaha.120.050281] [Citation(s) in RCA: 35] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
BACKGROUND Whereas regular exercise is associated with lower risk of cardiovascular disease and mortality, mechanisms of exercise-mediated health benefits remain less clear. We used metabolite profiling before and after acute exercise to delineate the metabolic architecture of exercise response patterns in humans. METHODS Cardiopulmonary exercise testing and metabolite profiling was performed on Framingham Heart Study participants (age 53±8 years, 63% women) with blood drawn at rest (n=471) and at peak exercise (n=411). RESULTS We observed changes in circulating levels for 502 of 588 measured metabolites from rest to peak exercise (exercise duration 11.9±2.1 minutes) at a 5% false discovery rate. Changes included reductions in metabolites implicated in insulin resistance (glutamate, -29%; P=1.5×10-55; dimethylguanidino valeric acid [DMGV], -18%; P=5.8×10-18) and increases in metabolites associated with lipolysis (1-methylnicotinamide, +33%; P=6.1×10-67), nitric oxide bioavailability (arginine/ornithine + citrulline, +29%; P=2.8×10-169), and adipose browning (12,13-dihydroxy-9Z-octadecenoic acid +26%; P=7.4×10-38), among other pathways relevant to cardiometabolic risk. We assayed 177 metabolites in a separate Framingham Heart Study replication sample (n=783, age 54±8 years, 51% women) and observed concordant changes in 164 metabolites (92.6%) at 5% false discovery rate. Exercise-induced metabolite changes were variably related to the amount of exercise performed (peak workload), sex, and body mass index. There was attenuation of favorable excursions in some metabolites in individuals with higher body mass index and greater excursions in select cardioprotective metabolites in women despite less exercise performed. Distinct preexercise metabolite levels were associated with different physiologic dimensions of fitness (eg, ventilatory efficiency, exercise blood pressure, peak Vo2). We identified 4 metabolite signatures of exercise response patterns that were then analyzed in a separate cohort (Framingham Offspring Study; n=2045, age 55±10 years, 51% women), 2 of which were associated with overall mortality over median follow-up of 23.1 years (P≤0.003 for both). CONCLUSIONS In a large sample of community-dwelling individuals, acute exercise elicits widespread changes in the circulating metabolome. Metabolic changes identify pathways central to cardiometabolic health, cardiovascular disease, and long-term outcome. These findings provide a detailed map of the metabolic response to acute exercise in humans and identify potential mechanisms responsible for the beneficial cardiometabolic effects of exercise for future study.
Collapse
Affiliation(s)
- Matthew Nayor
- Cardiology Division and the Simches Cardiovascular Research Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
| | - Ravi V. Shah
- Cardiology Division and the Simches Cardiovascular Research Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
| | - Patricia E. Miller
- Department of Biostatistics, Boston University School of Public Health, Boston, MA
| | - Jasmine B. Blodgett
- Cardiology Division and the Simches Cardiovascular Research Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
| | - Melissa Tanguay
- Cardiology Division and the Simches Cardiovascular Research Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
| | - Alexander R. Pico
- Institute of Data Science and Biotechnology, Gladstone Institutes, San Francisco, CA
| | - Venkatesh L. Murthy
- Division of Cardiovascular Medicine, Department of Medicine, University of Michigan, Ann Arbor
- Frankel Cardiovascular Center, University of Michigan, Ann Arbor
| | - Rajeev Malhotra
- Cardiology Division and the Simches Cardiovascular Research Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
- Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA
| | - Nicholas E. Houstis
- Cardiology Division and the Simches Cardiovascular Research Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
| | - Amy Deik
- Broad Institute of MIT and Harvard, Cambridge, MA
| | | | | | - Lucas Dailey
- Broad Institute of MIT and Harvard, Cambridge, MA
| | - Raghava S. Velagaleti
- Cardiology Section, Department of Medicine, Boston VA Healthcare System, West Roxbury, MA
| | - Stephanie A. Moore
- Cardiology Section, Department of Medicine, Boston VA Healthcare System, West Roxbury, MA
| | - Jennifer E. Ho
- Cardiology Division and the Simches Cardiovascular Research Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
| | - Aaron L. Baggish
- Cardiology Division and the Simches Cardiovascular Research Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
| | | | - Martin G. Larson
- Department of Biostatistics, Boston University School of Public Health, Boston, MA
- Boston University’s and National Heart, Lung, and Blood Institute’s Framingham Heart Study, Framingham, MA
| | - Ramachandran S. Vasan
- Boston University’s and National Heart, Lung, and Blood Institute’s Framingham Heart Study, Framingham, MA
- Sections of Preventive Medicine and Epidemiology, and Cardiology, Department of Medicine, Boston University School of Medicine, Boston, MA
| | - Gregory D. Lewis
- Cardiology Division and the Simches Cardiovascular Research Center, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA
- Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA
- Pulmonary Critical Care Unit, Massachusetts General Hospital, Boston, MA
| |
Collapse
|
10
|
Simic P, Kim W, Zhou W, Pierce KA, Chang W, Sykes DB, Aziz NB, Elmariah S, Ngo D, Pajevic PD, Govea N, Kestenbaum BR, de Boer IH, Cheng Z, Christov M, Chun J, Leaf DE, Waikar SS, Tager AM, Gerszten RE, Thadhani RI, Clish CB, Jüppner H, Wein MN, Rhee EP. Glycerol-3-phosphate is an FGF23 regulator derived from the injured kidney. J Clin Invest 2020; 130:1513-1526. [PMID: 32065590 PMCID: PMC7269595 DOI: 10.1172/jci131190] [Citation(s) in RCA: 70] [Impact Index Per Article: 17.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2019] [Accepted: 12/11/2019] [Indexed: 12/24/2022] Open
Abstract
Fibroblast growth factor 23 (FGF23) is a bone-derived hormone that controls blood phosphate levels by increasing renal phosphate excretion and reducing 1,25-dihydroxyvitamin D3 [1,25(OH)2D] production. Disorders of FGF23 homeostasis are associated with significant morbidity and mortality, but a fundamental understanding of what regulates FGF23 production is lacking. Because the kidney is the major end organ of FGF23 action, we hypothesized that it releases a factor that regulates FGF23 synthesis. Using aptamer-based proteomics and liquid chromatography-mass spectrometry-based (LC-MS-based) metabolomics, we profiled more than 1600 molecules in renal venous plasma obtained from human subjects. Renal vein glycerol-3-phosphate (G-3-P) had the strongest correlation with circulating FGF23. In mice, exogenous G-3-P stimulated bone and bone marrow FGF23 production through local G-3-P acyltransferase-mediated (GPAT-mediated) lysophosphatidic acid (LPA) synthesis. Further, the stimulatory effect of G-3-P and LPA on FGF23 required LPA receptor 1 (LPAR1). Acute kidney injury (AKI), which increases FGF23 levels, rapidly increased circulating G-3-P in humans and mice, and the effect of AKI on FGF23 was abrogated by GPAT inhibition or Lpar1 deletion. Together, our findings establish a role for kidney-derived G-3-P in mineral metabolism and outline potential targets to modulate FGF23 production during kidney injury.
Collapse
Affiliation(s)
- Petra Simic
- Nephrology Division and.,Endocrine Unit, Endocrinology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Wondong Kim
- Nephrology Division and.,Endocrine Unit, Endocrinology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Wen Zhou
- Nephrology Division and.,Endocrine Unit, Endocrinology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Kerry A Pierce
- Broad Institute, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, USA
| | - Wenhan Chang
- Endocrine Research Unit, San Francisco Veterans Affairs Medical Center, UCSF, San Francisco, California, USA
| | | | | | - Sammy Elmariah
- Cardiology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Debby Ngo
- Cardiovascular Research Center, Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| | - Paola Divieti Pajevic
- Department of Molecular and Cell Biology, Henry M. Goldman School of Dental Medicine, Boston University, Boston, Massachusetts, USA
| | - Nicolas Govea
- Endocrine Unit, Endocrinology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Bryan R Kestenbaum
- Kidney Research Institute, University of Washington Medicine and Northwest Kidney Centers, Seattle, Washington, USA
| | - Ian H de Boer
- Kidney Research Institute, University of Washington Medicine and Northwest Kidney Centers, Seattle, Washington, USA
| | - Zhiqiang Cheng
- Endocrine Research Unit, San Francisco Veterans Affairs Medical Center, UCSF, San Francisco, California, USA
| | - Marta Christov
- Department of Medicine, New York Medical College, Touro College, Valhalla, New York, USA
| | - Jerold Chun
- Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California, USA
| | - David E Leaf
- Division of Renal (Kidney) Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA
| | - Sushrut S Waikar
- Renal Section, Department of Medicine, Boston University Medical Center, Boston, Massachusetts, USA
| | - Andrew M Tager
- Division of Pulmonary and Critical Care Medicine, Department of Medicine, and
| | - Robert E Gerszten
- Broad Institute, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, USA.,Cardiovascular Research Center, Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA
| | | | - Clary B Clish
- Broad Institute, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, USA
| | - Harald Jüppner
- Endocrine Unit, Endocrinology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.,Pediatric Nephrology and Hypertension Program, Mass General for Children, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Marc N Wein
- Endocrine Unit, Endocrinology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Eugene P Rhee
- Nephrology Division and.,Endocrine Unit, Endocrinology Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA.,Broad Institute, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts, USA
| |
Collapse
|
11
|
Razquin C, Ruiz-Canela M, Clish CB, Li J, Toledo E, Dennis C, Liang L, Salas-Huetos A, Pierce KA, Guasch-Ferré M, Corella D, Ros E, Estruch R, Gómez-Gracia E, Fitó M, Lapetra J, Romaguera D, Alonso-Gómez A, Serra-Majem L, Salas-Salvadó J, Hu FB, Martínez-González MA. Lysine pathway metabolites and the risk of type 2 diabetes and cardiovascular disease in the PREDIMED study: results from two case-cohort studies. Cardiovasc Diabetol 2019; 18:151. [PMID: 31722714 PMCID: PMC6852717 DOI: 10.1186/s12933-019-0958-2] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/21/2019] [Accepted: 10/28/2019] [Indexed: 01/20/2023] Open
Abstract
Background The pandemic of cardiovascular disease (CVD) and type 2 diabetes (T2D) requires the identification of new predictor biomarkers. Biomarkers potentially modifiable with lifestyle changes deserve a special interest. Our aims were to analyze: (a) The associations of lysine, 2-aminoadipic acid (2-AAA) or pipecolic acid with the risk of T2D or CVD in the PREDIMED trial; (b) the effect of the dietary intervention on 1-year changes in these metabolites, and (c) whether the Mediterranean diet (MedDiet) interventions can modify the effects of these metabolites on CVD or T2D risk. Methods Two unstratified case-cohort studies nested within the PREDIMED trial were used. For CVD analyses, we selected 696 non-cases and 221 incident CVD cases; for T2D, we included 610 non-cases and 243 type 2 diabetes incident cases. Metabolites were quantified using liquid chromatography–tandem mass spectrometry, at baseline and after 1-year of intervention. Results In weighted Cox regression models, we found that baseline lysine (HR+1 SD increase = 1.26; 95% CI 1.06–1.51) and 2-AAA (HR+1 SD increase = 1.28; 95% CI 1.05–1.55) were both associated with a higher risk of T2D, but not with CVD. A significant interaction (p = 0.032) between baseline lysine and T2D on the risk of CVD was observed: subjects with prevalent T2D and high levels of lysine exhibited the highest risk of CVD. The intervention with MedDiet did not have a significant effect on 1-year changes of the metabolites. Conclusions Our results provide an independent prospective replication of the association of 2-AAA with future risk of T2D. We show an association of lysine with subsequent CVD risk, which is apparently diabetes-dependent. No evidence of effects of MedDiet intervention on lysine, 2-AAA or pipecolic acid changes was found. Trial registration ISRCTN35739639; registration date: 05/10/2005; recruitment start date 01/10/2003
Collapse
Affiliation(s)
- Cristina Razquin
- Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain.,IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.,CIBER Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, Madrid, Spain
| | - Miguel Ruiz-Canela
- Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain.,IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.,CIBER Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, Madrid, Spain
| | - Clary B Clish
- Broad Institute of MIT and Harvard University, Cambridge, USA
| | - Jun Li
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Spain.,Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, USA
| | - Estefania Toledo
- Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain.,IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.,CIBER Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, Madrid, Spain
| | - Courtney Dennis
- Broad Institute of MIT and Harvard University, Cambridge, USA
| | - Liming Liang
- Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, USA.,Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, USA
| | - Albert Salas-Huetos
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, Madrid, Spain.,Human Nutrition Unit, Faculty of Medicine and Health Sciences, Institut d'Investigació Sanitària Pere Virgili, Rovira i Virgili University, Reus, Spain
| | - Kerry A Pierce
- Broad Institute of MIT and Harvard University, Cambridge, USA
| | - Marta Guasch-Ferré
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Spain.,Human Nutrition Unit, Faculty of Medicine and Health Sciences, Institut d'Investigació Sanitària Pere Virgili, Rovira i Virgili University, Reus, Spain
| | - Dolores Corella
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, Madrid, Spain.,Department of Preventive Medicine, University of Valencia, Valencia, Spain
| | - Emilio Ros
- Lipid Clinic, Department of Endocrinology and Nutrition, Institut d'Investigacions Biomediques August Pi Sunyer (IDI- BAPS), Hospital Clinic, University of Barcelona, Barcelona, Spain
| | - Ramon Estruch
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, Madrid, Spain.,Department of Internal Medicine, Institut d'Investigacions Biomediques August Pi Sunyer (IDI-BAPS), Barcelona, Spain
| | | | - Montse Fitó
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, Madrid, Spain.,Cardiovascular and Nutrition Research Group, Institut de Recerca Hospital del Mar (IMIM), Barcelona, Spain
| | - Jose Lapetra
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, Madrid, Spain.,Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, Seville, Spain
| | - Dora Romaguera
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, Madrid, Spain.,Instituto de Investigación Sanitaria de Palma (IdISPa), University Hospital of Son Espases, Palma de Mallorca, Spain
| | | | - Lluis Serra-Majem
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, Madrid, Spain.,Research Institute of Biomedical and Health Sciences, University of Las Palmas de Gran Canaria, Las Palmas, Spain
| | - Jordi Salas-Salvadó
- CIBER Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, Madrid, Spain.,Human Nutrition Unit, Faculty of Medicine and Health Sciences, Institut d'Investigació Sanitària Pere Virgili, Rovira i Virgili University, Reus, Spain
| | - Frank B Hu
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Spain.,Channing Division for Network Medicine, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, USA
| | - Miguel A Martínez-González
- Department of Preventive Medicine and Public Health, University of Navarra, Pamplona, Spain. .,IdiSNA, Navarra Institute for Health Research, Pamplona, Spain. .,CIBER Fisiopatología de la Obesidad y Nutrición (CIBERObn), Instituto de Salud Carlos III, Madrid, Spain. .,Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Spain.
| |
Collapse
|
12
|
Paynter NP, Balasubramanian R, Giulianini F, Wang DD, Tinker LF, Gopal S, Deik AA, Bullock K, Pierce KA, Scott J, Martínez-González MA, Estruch R, Manson JE, Cook NR, Albert CM, Clish CB, Rexrode KM. Metabolic Predictors of Incident Coronary Heart Disease in Women. Circulation 2019; 137:841-853. [PMID: 29459470 DOI: 10.1161/circulationaha.117.029468] [Citation(s) in RCA: 156] [Impact Index Per Article: 31.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/12/2017] [Accepted: 12/11/2017] [Indexed: 12/25/2022]
Abstract
BACKGROUND Although metabolomic profiling offers promise for the prediction of coronary heart disease (CHD), and metabolic risk factors are more strongly associated with CHD in women than men, limited data are available for women. METHODS We applied a liquid chromatography-tandem mass spectrometry metabolomics platform to measure 371 metabolites in a discovery set of postmenopausal women (472 incident CHD cases, 472 controls) with validation in an independent set of postmenopausal women (312 incident CHD cases, 315 controls). RESULTS Eight metabolites, primarily oxidized lipids, were significantly dysregulated in cases after the adjustment for matching and CHD risk factors in both the discovery and validation data sets. One oxidized phospholipid, C34:2 hydroxy-phosphatidylcholine, remained associated with CHD after further adjustment for other validated metabolites. Subjects with C34:2 hydroxy-phosphatidylcholine levels in the highest quartile had a 4.7-fold increase in CHD odds in comparison with the lowest quartile; C34:2 hydroxy-phosphatidylcholine also significantly improved the area under the curve (P<0.01) for CHD. The C34:2 hydroxy-phosphatidylcholine findings were replicated in a third replication data set of 980 men and women (230 cardiovascular events) with a stronger association observed in women. CONCLUSIONS These data replicate known metabolite predictors, identify novel markers, and support the relationship between lipid oxidation and subsequent CHD.
Collapse
Affiliation(s)
- Nina P Paynter
- Division of Preventive Medicine (N.P.P., F.G., J.E.M., N.R.C., C.M.A., K.M.R.)
| | - Raji Balasubramanian
- Department of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts, Amherst (R.B.)
| | - Franco Giulianini
- Division of Preventive Medicine (N.P.P., F.G., J.E.M., N.R.C., C.M.A., K.M.R.)
| | - Dong D Wang
- Department of Epidemiology (D.D.W., J.E.M., N.R.C.).,Department of Nutrition (D.D.W., M.A.M.-G.), Harvard T.H. Chan School of Public Health, Boston, MA
| | - Lesley F Tinker
- Fred Hutchinson Cancer Research Center, Seattle, WA (L.F.T.)
| | - Shuba Gopal
- Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, MA (S.G., A.A.D., K.B., K.A.P., J.S., C.B.C.)
| | - Amy A Deik
- Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, MA (S.G., A.A.D., K.B., K.A.P., J.S., C.B.C.)
| | - Kevin Bullock
- Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, MA (S.G., A.A.D., K.B., K.A.P., J.S., C.B.C.)
| | - Kerry A Pierce
- Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, MA (S.G., A.A.D., K.B., K.A.P., J.S., C.B.C.)
| | - Justin Scott
- Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, MA (S.G., A.A.D., K.B., K.A.P., J.S., C.B.C.)
| | - Miguel A Martínez-González
- Department of Nutrition (D.D.W., M.A.M.-G.), Harvard T.H. Chan School of Public Health, Boston, MA.,Department of Preventive Medicine and Public Health, University of Navarra Medical School, Pamplona, Spain (M.A.M.-G.)
| | - Ramon Estruch
- Department of Internal Medicine, Institut d'Investigacions Biomèdiques August Pi Sunyer, Hospital Clínic, University of Barcelona, Spain (R.E.)
| | - JoAnn E Manson
- Division of Preventive Medicine (N.P.P., F.G., J.E.M., N.R.C., C.M.A., K.M.R.).,Department of Epidemiology (D.D.W., J.E.M., N.R.C.)
| | - Nancy R Cook
- Division of Preventive Medicine (N.P.P., F.G., J.E.M., N.R.C., C.M.A., K.M.R.).,Department of Epidemiology (D.D.W., J.E.M., N.R.C.)
| | - Christine M Albert
- Division of Preventive Medicine (N.P.P., F.G., J.E.M., N.R.C., C.M.A., K.M.R.)
| | - Clary B Clish
- Broad Institute of the Massachusetts Institute of Technology and Harvard University, Cambridge, MA (S.G., A.A.D., K.B., K.A.P., J.S., C.B.C.)
| | - Kathryn M Rexrode
- Division of Preventive Medicine (N.P.P., F.G., J.E.M., N.R.C., C.M.A., K.M.R.).,Division of Women's Health (K.M.R.), Brigham and Women's Hospital, Boston, MA
| |
Collapse
|
13
|
Bjornevik K, Zhang Z, O'Reilly ÉJ, Berry JD, Clish CB, Deik A, Jeanfavre S, Kato I, Kelly RS, Kolonel LN, Liang L, Marchand LL, McCullough ML, Paganoni S, Pierce KA, Schwarzschild MA, Shadyab AH, Wactawski-Wende J, Wang DD, Wang Y, Manson JE, Ascherio A. Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis. Neurology 2019; 92:e2089-e2100. [PMID: 30926684 DOI: 10.1212/wnl.0000000000007401] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2018] [Accepted: 02/11/2019] [Indexed: 12/11/2022] Open
Abstract
OBJECTIVE To identify prediagnostic plasma metabolomic biomarkers associated with amyotrophic lateral sclerosis (ALS). METHODS We conducted a global metabolomic study using a nested case-control study design within 5 prospective cohorts and identified 275 individuals who developed ALS during follow-up. We profiled plasma metabolites using liquid chromatography-mass spectrometry and identified 404 known metabolites. We used conditional logistic regression to evaluate the associations between metabolites and ALS risk. Further, we used machine learning analyses to determine whether the prediagnostic metabolomic profile could discriminate ALS cases from controls. RESULTS A total of 31 out of 404 identified metabolites were associated with ALS risk (p < 0.05). We observed inverse associations (n = 27) with plasma levels of diacylglycerides and triacylglycerides, urate, purine nucleosides, and some organic acids and derivatives, while we found positive associations for a cholesteryl ester, 2 phosphatidylcholines, and a sphingomyelin. The number of significant associations increased to 67 (63 inverse) in analyses restricted to cases with blood samples collected within 5 years of onset. None of these associations remained significant after multiple comparison adjustment. Further, we were not able to reliably distinguish individuals who became cases from controls based on their metabolomic profile using partial least squares discriminant analysis, elastic net regression, random forest, support vector machine, or weighted correlation network analyses. CONCLUSIONS Although the metabolomic profile in blood samples collected years before ALS diagnosis did not reliably separate presymptomatic ALS cases from controls, our results suggest that ALS is preceded by a broad, but poorly defined, metabolic dysregulation years before the disease onset.
Collapse
Affiliation(s)
- Kjetil Bjornevik
- From the Departments of Nutrition (K.B., Z.Z., É.J.O., D.D.W., A.A.) and Epidemiology (L.L., J.E.M., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; School of Public Health (É.J.O.), College of Medicine, University College Cork, Ireland; Department of Neurology (J.D.B., M.A.S.), Massachusetts General Hospital, Boston; Metabolomics Platform (C.B.C., A.D., S.J., K.A.P.), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Department of Oncology (I.K.), Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Channing Division of Network Medicine (R.S.K., A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Epidemiology Program (L.N.K., L.L.M.), University of Hawaii Cancer Center, Honolulu; Behavioral and Epidemiology Research Group (M.L.M.), American Cancer Society, Atlanta, GA; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.), Boston, MA; Family Medicine and Public Health (A.H.S.), School of Medicine, University of California San Diego; Epidemiology and Environmental Health, Public Health and Health Professions (J.W.-W.), University at Buffalo, NY; Behavioral and Epidemiology Research Group (Y.W.), American Cancer Society, Atlanta, GA; and Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
| | - Zhongli Zhang
- From the Departments of Nutrition (K.B., Z.Z., É.J.O., D.D.W., A.A.) and Epidemiology (L.L., J.E.M., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; School of Public Health (É.J.O.), College of Medicine, University College Cork, Ireland; Department of Neurology (J.D.B., M.A.S.), Massachusetts General Hospital, Boston; Metabolomics Platform (C.B.C., A.D., S.J., K.A.P.), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Department of Oncology (I.K.), Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Channing Division of Network Medicine (R.S.K., A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Epidemiology Program (L.N.K., L.L.M.), University of Hawaii Cancer Center, Honolulu; Behavioral and Epidemiology Research Group (M.L.M.), American Cancer Society, Atlanta, GA; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.), Boston, MA; Family Medicine and Public Health (A.H.S.), School of Medicine, University of California San Diego; Epidemiology and Environmental Health, Public Health and Health Professions (J.W.-W.), University at Buffalo, NY; Behavioral and Epidemiology Research Group (Y.W.), American Cancer Society, Atlanta, GA; and Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Éilis J O'Reilly
- From the Departments of Nutrition (K.B., Z.Z., É.J.O., D.D.W., A.A.) and Epidemiology (L.L., J.E.M., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; School of Public Health (É.J.O.), College of Medicine, University College Cork, Ireland; Department of Neurology (J.D.B., M.A.S.), Massachusetts General Hospital, Boston; Metabolomics Platform (C.B.C., A.D., S.J., K.A.P.), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Department of Oncology (I.K.), Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Channing Division of Network Medicine (R.S.K., A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Epidemiology Program (L.N.K., L.L.M.), University of Hawaii Cancer Center, Honolulu; Behavioral and Epidemiology Research Group (M.L.M.), American Cancer Society, Atlanta, GA; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.), Boston, MA; Family Medicine and Public Health (A.H.S.), School of Medicine, University of California San Diego; Epidemiology and Environmental Health, Public Health and Health Professions (J.W.-W.), University at Buffalo, NY; Behavioral and Epidemiology Research Group (Y.W.), American Cancer Society, Atlanta, GA; and Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - James D Berry
- From the Departments of Nutrition (K.B., Z.Z., É.J.O., D.D.W., A.A.) and Epidemiology (L.L., J.E.M., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; School of Public Health (É.J.O.), College of Medicine, University College Cork, Ireland; Department of Neurology (J.D.B., M.A.S.), Massachusetts General Hospital, Boston; Metabolomics Platform (C.B.C., A.D., S.J., K.A.P.), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Department of Oncology (I.K.), Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Channing Division of Network Medicine (R.S.K., A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Epidemiology Program (L.N.K., L.L.M.), University of Hawaii Cancer Center, Honolulu; Behavioral and Epidemiology Research Group (M.L.M.), American Cancer Society, Atlanta, GA; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.), Boston, MA; Family Medicine and Public Health (A.H.S.), School of Medicine, University of California San Diego; Epidemiology and Environmental Health, Public Health and Health Professions (J.W.-W.), University at Buffalo, NY; Behavioral and Epidemiology Research Group (Y.W.), American Cancer Society, Atlanta, GA; and Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Clary B Clish
- From the Departments of Nutrition (K.B., Z.Z., É.J.O., D.D.W., A.A.) and Epidemiology (L.L., J.E.M., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; School of Public Health (É.J.O.), College of Medicine, University College Cork, Ireland; Department of Neurology (J.D.B., M.A.S.), Massachusetts General Hospital, Boston; Metabolomics Platform (C.B.C., A.D., S.J., K.A.P.), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Department of Oncology (I.K.), Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Channing Division of Network Medicine (R.S.K., A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Epidemiology Program (L.N.K., L.L.M.), University of Hawaii Cancer Center, Honolulu; Behavioral and Epidemiology Research Group (M.L.M.), American Cancer Society, Atlanta, GA; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.), Boston, MA; Family Medicine and Public Health (A.H.S.), School of Medicine, University of California San Diego; Epidemiology and Environmental Health, Public Health and Health Professions (J.W.-W.), University at Buffalo, NY; Behavioral and Epidemiology Research Group (Y.W.), American Cancer Society, Atlanta, GA; and Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Amy Deik
- From the Departments of Nutrition (K.B., Z.Z., É.J.O., D.D.W., A.A.) and Epidemiology (L.L., J.E.M., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; School of Public Health (É.J.O.), College of Medicine, University College Cork, Ireland; Department of Neurology (J.D.B., M.A.S.), Massachusetts General Hospital, Boston; Metabolomics Platform (C.B.C., A.D., S.J., K.A.P.), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Department of Oncology (I.K.), Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Channing Division of Network Medicine (R.S.K., A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Epidemiology Program (L.N.K., L.L.M.), University of Hawaii Cancer Center, Honolulu; Behavioral and Epidemiology Research Group (M.L.M.), American Cancer Society, Atlanta, GA; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.), Boston, MA; Family Medicine and Public Health (A.H.S.), School of Medicine, University of California San Diego; Epidemiology and Environmental Health, Public Health and Health Professions (J.W.-W.), University at Buffalo, NY; Behavioral and Epidemiology Research Group (Y.W.), American Cancer Society, Atlanta, GA; and Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Sarah Jeanfavre
- From the Departments of Nutrition (K.B., Z.Z., É.J.O., D.D.W., A.A.) and Epidemiology (L.L., J.E.M., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; School of Public Health (É.J.O.), College of Medicine, University College Cork, Ireland; Department of Neurology (J.D.B., M.A.S.), Massachusetts General Hospital, Boston; Metabolomics Platform (C.B.C., A.D., S.J., K.A.P.), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Department of Oncology (I.K.), Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Channing Division of Network Medicine (R.S.K., A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Epidemiology Program (L.N.K., L.L.M.), University of Hawaii Cancer Center, Honolulu; Behavioral and Epidemiology Research Group (M.L.M.), American Cancer Society, Atlanta, GA; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.), Boston, MA; Family Medicine and Public Health (A.H.S.), School of Medicine, University of California San Diego; Epidemiology and Environmental Health, Public Health and Health Professions (J.W.-W.), University at Buffalo, NY; Behavioral and Epidemiology Research Group (Y.W.), American Cancer Society, Atlanta, GA; and Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Ikuko Kato
- From the Departments of Nutrition (K.B., Z.Z., É.J.O., D.D.W., A.A.) and Epidemiology (L.L., J.E.M., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; School of Public Health (É.J.O.), College of Medicine, University College Cork, Ireland; Department of Neurology (J.D.B., M.A.S.), Massachusetts General Hospital, Boston; Metabolomics Platform (C.B.C., A.D., S.J., K.A.P.), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Department of Oncology (I.K.), Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Channing Division of Network Medicine (R.S.K., A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Epidemiology Program (L.N.K., L.L.M.), University of Hawaii Cancer Center, Honolulu; Behavioral and Epidemiology Research Group (M.L.M.), American Cancer Society, Atlanta, GA; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.), Boston, MA; Family Medicine and Public Health (A.H.S.), School of Medicine, University of California San Diego; Epidemiology and Environmental Health, Public Health and Health Professions (J.W.-W.), University at Buffalo, NY; Behavioral and Epidemiology Research Group (Y.W.), American Cancer Society, Atlanta, GA; and Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Rachel S Kelly
- From the Departments of Nutrition (K.B., Z.Z., É.J.O., D.D.W., A.A.) and Epidemiology (L.L., J.E.M., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; School of Public Health (É.J.O.), College of Medicine, University College Cork, Ireland; Department of Neurology (J.D.B., M.A.S.), Massachusetts General Hospital, Boston; Metabolomics Platform (C.B.C., A.D., S.J., K.A.P.), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Department of Oncology (I.K.), Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Channing Division of Network Medicine (R.S.K., A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Epidemiology Program (L.N.K., L.L.M.), University of Hawaii Cancer Center, Honolulu; Behavioral and Epidemiology Research Group (M.L.M.), American Cancer Society, Atlanta, GA; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.), Boston, MA; Family Medicine and Public Health (A.H.S.), School of Medicine, University of California San Diego; Epidemiology and Environmental Health, Public Health and Health Professions (J.W.-W.), University at Buffalo, NY; Behavioral and Epidemiology Research Group (Y.W.), American Cancer Society, Atlanta, GA; and Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Laurence N Kolonel
- From the Departments of Nutrition (K.B., Z.Z., É.J.O., D.D.W., A.A.) and Epidemiology (L.L., J.E.M., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; School of Public Health (É.J.O.), College of Medicine, University College Cork, Ireland; Department of Neurology (J.D.B., M.A.S.), Massachusetts General Hospital, Boston; Metabolomics Platform (C.B.C., A.D., S.J., K.A.P.), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Department of Oncology (I.K.), Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Channing Division of Network Medicine (R.S.K., A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Epidemiology Program (L.N.K., L.L.M.), University of Hawaii Cancer Center, Honolulu; Behavioral and Epidemiology Research Group (M.L.M.), American Cancer Society, Atlanta, GA; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.), Boston, MA; Family Medicine and Public Health (A.H.S.), School of Medicine, University of California San Diego; Epidemiology and Environmental Health, Public Health and Health Professions (J.W.-W.), University at Buffalo, NY; Behavioral and Epidemiology Research Group (Y.W.), American Cancer Society, Atlanta, GA; and Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Liming Liang
- From the Departments of Nutrition (K.B., Z.Z., É.J.O., D.D.W., A.A.) and Epidemiology (L.L., J.E.M., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; School of Public Health (É.J.O.), College of Medicine, University College Cork, Ireland; Department of Neurology (J.D.B., M.A.S.), Massachusetts General Hospital, Boston; Metabolomics Platform (C.B.C., A.D., S.J., K.A.P.), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Department of Oncology (I.K.), Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Channing Division of Network Medicine (R.S.K., A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Epidemiology Program (L.N.K., L.L.M.), University of Hawaii Cancer Center, Honolulu; Behavioral and Epidemiology Research Group (M.L.M.), American Cancer Society, Atlanta, GA; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.), Boston, MA; Family Medicine and Public Health (A.H.S.), School of Medicine, University of California San Diego; Epidemiology and Environmental Health, Public Health and Health Professions (J.W.-W.), University at Buffalo, NY; Behavioral and Epidemiology Research Group (Y.W.), American Cancer Society, Atlanta, GA; and Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Loic Le Marchand
- From the Departments of Nutrition (K.B., Z.Z., É.J.O., D.D.W., A.A.) and Epidemiology (L.L., J.E.M., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; School of Public Health (É.J.O.), College of Medicine, University College Cork, Ireland; Department of Neurology (J.D.B., M.A.S.), Massachusetts General Hospital, Boston; Metabolomics Platform (C.B.C., A.D., S.J., K.A.P.), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Department of Oncology (I.K.), Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Channing Division of Network Medicine (R.S.K., A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Epidemiology Program (L.N.K., L.L.M.), University of Hawaii Cancer Center, Honolulu; Behavioral and Epidemiology Research Group (M.L.M.), American Cancer Society, Atlanta, GA; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.), Boston, MA; Family Medicine and Public Health (A.H.S.), School of Medicine, University of California San Diego; Epidemiology and Environmental Health, Public Health and Health Professions (J.W.-W.), University at Buffalo, NY; Behavioral and Epidemiology Research Group (Y.W.), American Cancer Society, Atlanta, GA; and Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Marjorie L McCullough
- From the Departments of Nutrition (K.B., Z.Z., É.J.O., D.D.W., A.A.) and Epidemiology (L.L., J.E.M., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; School of Public Health (É.J.O.), College of Medicine, University College Cork, Ireland; Department of Neurology (J.D.B., M.A.S.), Massachusetts General Hospital, Boston; Metabolomics Platform (C.B.C., A.D., S.J., K.A.P.), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Department of Oncology (I.K.), Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Channing Division of Network Medicine (R.S.K., A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Epidemiology Program (L.N.K., L.L.M.), University of Hawaii Cancer Center, Honolulu; Behavioral and Epidemiology Research Group (M.L.M.), American Cancer Society, Atlanta, GA; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.), Boston, MA; Family Medicine and Public Health (A.H.S.), School of Medicine, University of California San Diego; Epidemiology and Environmental Health, Public Health and Health Professions (J.W.-W.), University at Buffalo, NY; Behavioral and Epidemiology Research Group (Y.W.), American Cancer Society, Atlanta, GA; and Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Sabrina Paganoni
- From the Departments of Nutrition (K.B., Z.Z., É.J.O., D.D.W., A.A.) and Epidemiology (L.L., J.E.M., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; School of Public Health (É.J.O.), College of Medicine, University College Cork, Ireland; Department of Neurology (J.D.B., M.A.S.), Massachusetts General Hospital, Boston; Metabolomics Platform (C.B.C., A.D., S.J., K.A.P.), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Department of Oncology (I.K.), Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Channing Division of Network Medicine (R.S.K., A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Epidemiology Program (L.N.K., L.L.M.), University of Hawaii Cancer Center, Honolulu; Behavioral and Epidemiology Research Group (M.L.M.), American Cancer Society, Atlanta, GA; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.), Boston, MA; Family Medicine and Public Health (A.H.S.), School of Medicine, University of California San Diego; Epidemiology and Environmental Health, Public Health and Health Professions (J.W.-W.), University at Buffalo, NY; Behavioral and Epidemiology Research Group (Y.W.), American Cancer Society, Atlanta, GA; and Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Kerry A Pierce
- From the Departments of Nutrition (K.B., Z.Z., É.J.O., D.D.W., A.A.) and Epidemiology (L.L., J.E.M., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; School of Public Health (É.J.O.), College of Medicine, University College Cork, Ireland; Department of Neurology (J.D.B., M.A.S.), Massachusetts General Hospital, Boston; Metabolomics Platform (C.B.C., A.D., S.J., K.A.P.), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Department of Oncology (I.K.), Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Channing Division of Network Medicine (R.S.K., A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Epidemiology Program (L.N.K., L.L.M.), University of Hawaii Cancer Center, Honolulu; Behavioral and Epidemiology Research Group (M.L.M.), American Cancer Society, Atlanta, GA; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.), Boston, MA; Family Medicine and Public Health (A.H.S.), School of Medicine, University of California San Diego; Epidemiology and Environmental Health, Public Health and Health Professions (J.W.-W.), University at Buffalo, NY; Behavioral and Epidemiology Research Group (Y.W.), American Cancer Society, Atlanta, GA; and Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Michael A Schwarzschild
- From the Departments of Nutrition (K.B., Z.Z., É.J.O., D.D.W., A.A.) and Epidemiology (L.L., J.E.M., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; School of Public Health (É.J.O.), College of Medicine, University College Cork, Ireland; Department of Neurology (J.D.B., M.A.S.), Massachusetts General Hospital, Boston; Metabolomics Platform (C.B.C., A.D., S.J., K.A.P.), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Department of Oncology (I.K.), Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Channing Division of Network Medicine (R.S.K., A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Epidemiology Program (L.N.K., L.L.M.), University of Hawaii Cancer Center, Honolulu; Behavioral and Epidemiology Research Group (M.L.M.), American Cancer Society, Atlanta, GA; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.), Boston, MA; Family Medicine and Public Health (A.H.S.), School of Medicine, University of California San Diego; Epidemiology and Environmental Health, Public Health and Health Professions (J.W.-W.), University at Buffalo, NY; Behavioral and Epidemiology Research Group (Y.W.), American Cancer Society, Atlanta, GA; and Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Aladdin H Shadyab
- From the Departments of Nutrition (K.B., Z.Z., É.J.O., D.D.W., A.A.) and Epidemiology (L.L., J.E.M., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; School of Public Health (É.J.O.), College of Medicine, University College Cork, Ireland; Department of Neurology (J.D.B., M.A.S.), Massachusetts General Hospital, Boston; Metabolomics Platform (C.B.C., A.D., S.J., K.A.P.), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Department of Oncology (I.K.), Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Channing Division of Network Medicine (R.S.K., A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Epidemiology Program (L.N.K., L.L.M.), University of Hawaii Cancer Center, Honolulu; Behavioral and Epidemiology Research Group (M.L.M.), American Cancer Society, Atlanta, GA; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.), Boston, MA; Family Medicine and Public Health (A.H.S.), School of Medicine, University of California San Diego; Epidemiology and Environmental Health, Public Health and Health Professions (J.W.-W.), University at Buffalo, NY; Behavioral and Epidemiology Research Group (Y.W.), American Cancer Society, Atlanta, GA; and Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Jean Wactawski-Wende
- From the Departments of Nutrition (K.B., Z.Z., É.J.O., D.D.W., A.A.) and Epidemiology (L.L., J.E.M., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; School of Public Health (É.J.O.), College of Medicine, University College Cork, Ireland; Department of Neurology (J.D.B., M.A.S.), Massachusetts General Hospital, Boston; Metabolomics Platform (C.B.C., A.D., S.J., K.A.P.), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Department of Oncology (I.K.), Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Channing Division of Network Medicine (R.S.K., A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Epidemiology Program (L.N.K., L.L.M.), University of Hawaii Cancer Center, Honolulu; Behavioral and Epidemiology Research Group (M.L.M.), American Cancer Society, Atlanta, GA; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.), Boston, MA; Family Medicine and Public Health (A.H.S.), School of Medicine, University of California San Diego; Epidemiology and Environmental Health, Public Health and Health Professions (J.W.-W.), University at Buffalo, NY; Behavioral and Epidemiology Research Group (Y.W.), American Cancer Society, Atlanta, GA; and Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Dong D Wang
- From the Departments of Nutrition (K.B., Z.Z., É.J.O., D.D.W., A.A.) and Epidemiology (L.L., J.E.M., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; School of Public Health (É.J.O.), College of Medicine, University College Cork, Ireland; Department of Neurology (J.D.B., M.A.S.), Massachusetts General Hospital, Boston; Metabolomics Platform (C.B.C., A.D., S.J., K.A.P.), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Department of Oncology (I.K.), Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Channing Division of Network Medicine (R.S.K., A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Epidemiology Program (L.N.K., L.L.M.), University of Hawaii Cancer Center, Honolulu; Behavioral and Epidemiology Research Group (M.L.M.), American Cancer Society, Atlanta, GA; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.), Boston, MA; Family Medicine and Public Health (A.H.S.), School of Medicine, University of California San Diego; Epidemiology and Environmental Health, Public Health and Health Professions (J.W.-W.), University at Buffalo, NY; Behavioral and Epidemiology Research Group (Y.W.), American Cancer Society, Atlanta, GA; and Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Ying Wang
- From the Departments of Nutrition (K.B., Z.Z., É.J.O., D.D.W., A.A.) and Epidemiology (L.L., J.E.M., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; School of Public Health (É.J.O.), College of Medicine, University College Cork, Ireland; Department of Neurology (J.D.B., M.A.S.), Massachusetts General Hospital, Boston; Metabolomics Platform (C.B.C., A.D., S.J., K.A.P.), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Department of Oncology (I.K.), Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Channing Division of Network Medicine (R.S.K., A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Epidemiology Program (L.N.K., L.L.M.), University of Hawaii Cancer Center, Honolulu; Behavioral and Epidemiology Research Group (M.L.M.), American Cancer Society, Atlanta, GA; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.), Boston, MA; Family Medicine and Public Health (A.H.S.), School of Medicine, University of California San Diego; Epidemiology and Environmental Health, Public Health and Health Professions (J.W.-W.), University at Buffalo, NY; Behavioral and Epidemiology Research Group (Y.W.), American Cancer Society, Atlanta, GA; and Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - JoAnn E Manson
- From the Departments of Nutrition (K.B., Z.Z., É.J.O., D.D.W., A.A.) and Epidemiology (L.L., J.E.M., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; School of Public Health (É.J.O.), College of Medicine, University College Cork, Ireland; Department of Neurology (J.D.B., M.A.S.), Massachusetts General Hospital, Boston; Metabolomics Platform (C.B.C., A.D., S.J., K.A.P.), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Department of Oncology (I.K.), Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Channing Division of Network Medicine (R.S.K., A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Epidemiology Program (L.N.K., L.L.M.), University of Hawaii Cancer Center, Honolulu; Behavioral and Epidemiology Research Group (M.L.M.), American Cancer Society, Atlanta, GA; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.), Boston, MA; Family Medicine and Public Health (A.H.S.), School of Medicine, University of California San Diego; Epidemiology and Environmental Health, Public Health and Health Professions (J.W.-W.), University at Buffalo, NY; Behavioral and Epidemiology Research Group (Y.W.), American Cancer Society, Atlanta, GA; and Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| | - Alberto Ascherio
- From the Departments of Nutrition (K.B., Z.Z., É.J.O., D.D.W., A.A.) and Epidemiology (L.L., J.E.M., A.A.), Harvard T.H. Chan School of Public Health, Boston, MA; School of Public Health (É.J.O.), College of Medicine, University College Cork, Ireland; Department of Neurology (J.D.B., M.A.S.), Massachusetts General Hospital, Boston; Metabolomics Platform (C.B.C., A.D., S.J., K.A.P.), Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA; Department of Oncology (I.K.), Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI; Channing Division of Network Medicine (R.S.K., A.A.), Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Epidemiology Program (L.N.K., L.L.M.), University of Hawaii Cancer Center, Honolulu; Behavioral and Epidemiology Research Group (M.L.M.), American Cancer Society, Atlanta, GA; Department of Physical Medicine and Rehabilitation (S.P.), Spaulding Rehabilitation Hospital and Massachusetts General Hospital; Harvard Medical School (S.P., M.A.S.), Boston, MA; Family Medicine and Public Health (A.H.S.), School of Medicine, University of California San Diego; Epidemiology and Environmental Health, Public Health and Health Professions (J.W.-W.), University at Buffalo, NY; Behavioral and Epidemiology Research Group (Y.W.), American Cancer Society, Atlanta, GA; and Department of Medicine (J.E.M.), Brigham and Women's Hospital, Harvard Medical School, Boston, MA
| |
Collapse
|
14
|
Steinhauser ML, Olenchock BA, O'Keefe J, Lun M, Pierce KA, Lee H, Pantano L, Klibanski A, Shulman GI, Clish CB, Fazeli PK. The circulating metabolome of human starvation. JCI Insight 2018; 3:121434. [PMID: 30135314 DOI: 10.1172/jci.insight.121434] [Citation(s) in RCA: 72] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2018] [Accepted: 07/10/2018] [Indexed: 12/17/2022] Open
Abstract
The human adaptive starvation response allows for survival during long-term caloric deprivation. Whether the physiology of starvation is adaptive or maladaptive is context dependent: activation of pathways by caloric restriction may promote longevity, yet in the context of caloric excess, the same pathways may contribute to obesity. Here, we performed plasma metabolite profiling of longitudinally collected samples during a 10-day, 0-calorie fast in humans. We identify classical milestones in adaptive starvation, including the early consumption of gluconeogenic amino acids and the subsequent surge in plasma nonesterified fatty acids that marks the shift from carbohydrate to lipid metabolism, and demonstrate findings, including (a) the preferential release of unsaturated fatty acids and an associated shift in plasma lipid species with high degrees of unsaturation and (b) evidence that acute, starvation-mediated hypoleptinemia may be a driver of the transition from glucose to lipid metabolism in humans.
Collapse
Affiliation(s)
- Matthew L Steinhauser
- Department of Medicine, Division of Genetics, and.,Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.,Harvard Medical School, Boston, Massachusetts, USA.,Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
| | - Benjamin A Olenchock
- Department of Medicine, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.,Harvard Medical School, Boston, Massachusetts, USA.,Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
| | - John O'Keefe
- Department of Medicine, Division of Genetics, and
| | - Mingyue Lun
- Department of Medicine, Division of Genetics, and
| | - Kerry A Pierce
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
| | - Hang Lee
- Harvard Medical School, Boston, Massachusetts, USA.,MGH Biostatistics Center, Boston, Massachusetts, USA
| | - Lorena Pantano
- Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA
| | - Anne Klibanski
- Harvard Medical School, Boston, Massachusetts, USA.,Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| | - Gerald I Shulman
- Departments of Internal Medicine and Cellular and Molecular Physiology and Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Clary B Clish
- Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA
| | - Pouneh K Fazeli
- Harvard Medical School, Boston, Massachusetts, USA.,Neuroendocrine Unit, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
| |
Collapse
|
15
|
Rusu V, Hoch E, Mercader JM, Tenen DE, Gymrek M, Hartigan CR, DeRan M, von Grotthuss M, Fontanillas P, Spooner A, Guzman G, Deik AA, Pierce KA, Dennis C, Clish CB, Carr SA, Wagner BK, Schenone M, Ng MCY, Chen BH, Centeno-Cruz F, Zerrweck C, Orozco L, Altshuler DM, Schreiber SL, Florez JC, Jacobs SBR, Lander ES. Type 2 Diabetes Variants Disrupt Function of SLC16A11 through Two Distinct Mechanisms. Cell 2017; 170:199-212.e20. [PMID: 28666119 DOI: 10.1016/j.cell.2017.06.011] [Citation(s) in RCA: 108] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2016] [Revised: 03/16/2017] [Accepted: 06/08/2017] [Indexed: 01/08/2023]
Abstract
Type 2 diabetes (T2D) affects Latinos at twice the rate seen in populations of European descent. We recently identified a risk haplotype spanning SLC16A11 that explains ∼20% of the increased T2D prevalence in Mexico. Here, through genetic fine-mapping, we define a set of tightly linked variants likely to contain the causal allele(s). We show that variants on the T2D-associated haplotype have two distinct effects: (1) decreasing SLC16A11 expression in liver and (2) disrupting a key interaction with basigin, thereby reducing cell-surface localization. Both independent mechanisms reduce SLC16A11 function and suggest SLC16A11 is the causal gene at this locus. To gain insight into how SLC16A11 disruption impacts T2D risk, we demonstrate that SLC16A11 is a proton-coupled monocarboxylate transporter and that genetic perturbation of SLC16A11 induces changes in fatty acid and lipid metabolism that are associated with increased T2D risk. Our findings suggest that increasing SLC16A11 function could be therapeutically beneficial for T2D. VIDEO ABSTRACT.
Collapse
Affiliation(s)
- Victor Rusu
- Program in Biological and Biomedical Sciences, Harvard Medical School, Boston, MA 02115, USA; Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Eitan Hoch
- Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Metabolism Program, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Josep M Mercader
- Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Barcelona Supercomputing Center (BSC), Joint BSC-CRG-IRB Research Program in Computational Biology, 08034 Barcelona, Spain
| | - Danielle E Tenen
- Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Division of Endocrinology, Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
| | - Melissa Gymrek
- Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Analytic and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA 02114, USA
| | | | - Michael DeRan
- Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Marcin von Grotthuss
- Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Pierre Fontanillas
- Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Alexandra Spooner
- Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Gaelen Guzman
- Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Amy A Deik
- Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Kerry A Pierce
- Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Courtney Dennis
- Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Clary B Clish
- Metabolism Program, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Steven A Carr
- Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | | | - Monica Schenone
- Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA
| | - Maggie C Y Ng
- Center for Genomics and Personalized Medicine Research, Center for Diabetes Research, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA
| | - Brian H Chen
- Longitudinal Studies Section, Translational Gerontology Branch, Intramural Research Program, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA
| | | | | | | | - Carlos Zerrweck
- The Obesity Clinic at Hospital General Tlahuac, 13250 Mexico City, Mexico
| | - Lorena Orozco
- Instituto Nacional de Medicina Genómica, Tlalpan, 14610 Mexico City, Mexico
| | - David M Altshuler
- Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Genetics, Harvard Medical School, Boston, MA 02115, USA; Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA; Department of Biology, MIT, Cambridge, MA 02139, USA
| | | | - Jose C Florez
- Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Metabolism Program, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Medicine, Harvard Medical School, Boston, MA 02115, USA.
| | - Suzanne B R Jacobs
- Program in Medical and Population Genetics, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Metabolism Program, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Eric S Lander
- Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA; Department of Biology, MIT, Cambridge, MA 02139, USA; Department of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
| |
Collapse
|
16
|
Sykes DB, Kfoury YS, Mercier FE, Wawer MJ, Law JM, Haynes MK, Lewis TA, Schajnovitz A, Jain E, Lee D, Meyer H, Pierce KA, Tolliday NJ, Waller A, Ferrara SJ, Eheim AL, Stoeckigt D, Maxcy KL, Cobert JM, Bachand J, Szekely BA, Mukherjee S, Sklar LA, Kotz JD, Clish CB, Sadreyev RI, Clemons PA, Janzer A, Schreiber SL, Scadden DT. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia. Cell 2016; 167:171-186.e15. [PMID: 27641501 DOI: 10.1016/j.cell.2016.08.057] [Citation(s) in RCA: 307] [Impact Index Per Article: 38.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2015] [Revised: 06/01/2016] [Accepted: 08/23/2016] [Indexed: 10/21/2022]
Abstract
While acute myeloid leukemia (AML) comprises many disparate genetic subtypes, one shared hallmark is the arrest of leukemic myeloblasts at an immature and self-renewing stage of development. Therapies that overcome differentiation arrest represent a powerful treatment strategy. We leveraged the observation that the majority of AML, despite their genetically heterogeneity, share in the expression of HoxA9, a gene normally downregulated during myeloid differentiation. Using a conditional HoxA9 model system, we performed a high-throughput phenotypic screen and defined compounds that overcame differentiation blockade. Target identification led to the unanticipated discovery that inhibition of the enzyme dihydroorotate dehydrogenase (DHODH) enables myeloid differentiation in human and mouse AML models. In vivo, DHODH inhibitors reduced leukemic cell burden, decreased levels of leukemia-initiating cells, and improved survival. These data demonstrate the role of DHODH as a metabolic regulator of differentiation and point to its inhibition as a strategy for overcoming differentiation blockade in AML.
Collapse
Affiliation(s)
- David B Sykes
- Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA.
| | - Youmna S Kfoury
- Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA
| | - François E Mercier
- Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA
| | - Mathias J Wawer
- Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| | - Jason M Law
- Center for the Science of Therapeutics, Broad Institute, Cambridge, MA 02142, USA; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA
| | - Mark K Haynes
- Center for Molecular Discovery, University of New Mexico, Albuquerque, NM 87131, USA
| | - Timothy A Lewis
- Center for the Science of Therapeutics, Broad Institute, Cambridge, MA 02142, USA
| | - Amir Schajnovitz
- Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA
| | - Esha Jain
- Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Dongjun Lee
- Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA
| | | | - Kerry A Pierce
- Metabolite Profiling Platform, Broad Institute, Cambridge, MA 02142, USA
| | - Nicola J Tolliday
- Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| | - Anna Waller
- Center for Molecular Discovery, University of New Mexico, Albuquerque, NM 87131, USA
| | - Steven J Ferrara
- Center for the Development of Therapeutics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
| | | | | | - Katrina L Maxcy
- Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Julien M Cobert
- Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Jacqueline Bachand
- Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Brian A Szekely
- Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA
| | - Siddhartha Mukherjee
- Irving Cancer Research Center, Columbia University School of Medicine, New York, NY 10032, USA
| | - Larry A Sklar
- Center for Molecular Discovery, University of New Mexico, Albuquerque, NM 87131, USA
| | - Joanne D Kotz
- Center for the Science of Therapeutics, Broad Institute, Cambridge, MA 02142, USA
| | - Clary B Clish
- Metabolite Profiling Platform, Broad Institute, Cambridge, MA 02142, USA
| | - Ruslan I Sadreyev
- Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
| | - Paul A Clemons
- Center for the Science of Therapeutics, Broad Institute, Cambridge, MA 02142, USA
| | | | - Stuart L Schreiber
- Center for the Science of Therapeutics, Broad Institute, Cambridge, MA 02142, USA; Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA; Howard Hughes Medical Institute, Cambridge, MA 02138, USA
| | - David T Scadden
- Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA 02114, USA; Cancer Center, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Harvard Stem Cell Institute, Cambridge, MA 02138, USA.
| |
Collapse
|
17
|
Olenchock BA, Moslehi J, Baik AH, Davidson SM, Williams J, Gibson WJ, Chakraborty AA, Pierce KA, Miller CM, Hanse EA, Kelekar A, Sullivan LB, Wagers AJ, Clish CB, Vander Heiden MG, Kaelin WG. EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection. Cell 2016; 164:884-95. [PMID: 26919427 DOI: 10.1016/j.cell.2016.02.006] [Citation(s) in RCA: 94] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2015] [Revised: 12/12/2015] [Accepted: 02/01/2016] [Indexed: 12/30/2022]
Abstract
Ischemic preconditioning is the phenomenon whereby brief periods of sublethal ischemia protect against a subsequent, more prolonged, ischemic insult. In remote ischemic preconditioning (RIPC), ischemia to one organ protects others organs at a distance. We created mouse models to ask if inhibition of the alpha-ketoglutarate (αKG)-dependent dioxygenase Egln1, which senses oxygen and regulates the hypoxia-inducible factor (HIF) transcription factor, could suffice to mediate local and remote ischemic preconditioning. Using somatic gene deletion and a pharmacological inhibitor, we found that inhibiting Egln1 systemically or in skeletal muscles protects mice against myocardial ischemia-reperfusion (I/R) injury. Parabiosis experiments confirmed that RIPC in this latter model was mediated by a secreted factor. Egln1 loss causes accumulation of circulating αKG, which drives hepatic production and secretion of kynurenic acid (KYNA) that is necessary and sufficient to mediate cardiac ischemic protection in this setting.
Collapse
Affiliation(s)
- Benjamin A Olenchock
- Division of Cardiovascular Medicine, Department of Medicine, The Brigham and Women's Hospital, Boston, MA 02115, USA; Harvard Medical School, Boston, MA 02115, USA; Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Javid Moslehi
- Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt School of Medicine, Nashville, TN 37235, USA
| | - Alan H Baik
- Department of Medicine, University of California, San Francisco, San Francisco, CA 94117, USA
| | - Shawn M Davidson
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Jeremy Williams
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
| | - William J Gibson
- Harvard Medical School, Boston, MA 02115, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
| | | | - Kerry A Pierce
- Metabolomics Platform, Broad Institute, Cambridge, MA 02142, USA
| | - Christine M Miller
- Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Joslin Diabetes Center, Boston, MA 02215, USA
| | - Eric A Hanse
- Department of Laboratory Medicine and Pathology and Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
| | - Ameeta Kelekar
- Department of Laboratory Medicine and Pathology and Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
| | - Lucas B Sullivan
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Amy J Wagers
- Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA; Joslin Diabetes Center, Boston, MA 02215, USA
| | - Clary B Clish
- Metabolomics Platform, Broad Institute, Cambridge, MA 02142, USA
| | - Matthew G Vander Heiden
- Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
| | - William G Kaelin
- Harvard Medical School, Boston, MA 02115, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA.
| |
Collapse
|
18
|
Joyal JS, Sun Y, Gantner ML, Shao Z, Evans LP, Saba N, Fredrick T, Burnim S, Kim JS, Patel G, Juan AM, Hurst CG, Hatton CJ, Cui Z, Pierce KA, Bherer P, Aguilar E, Powner MB, Vevis K, Boisvert M, Fu Z, Levy E, Fruttiger M, Packard A, Rezende FA, Maranda B, Sapieha P, Chen J, Friedlander M, Clish CB, Smith LEH. Corrigendum: Retinal lipid and glucose metabolism dictates angiogenesis through the lipid sensor Ffar1. Nat Med 2016; 22:692. [PMID: 27270778 DOI: 10.1038/nm0616-692a] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
19
|
Rhee EP, Clish CB, Wenger J, Roy J, Elmariah S, Pierce KA, Bullock K, Anderson AH, Gerszten RE, Feldman HI. Metabolomics of Chronic Kidney Disease Progression: A Case-Control Analysis in the Chronic Renal Insufficiency Cohort Study. Am J Nephrol 2016; 43:366-74. [PMID: 27172772 DOI: 10.1159/000446484] [Citation(s) in RCA: 52] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2016] [Accepted: 04/24/2016] [Indexed: 01/09/2023]
Abstract
BACKGROUND Whereas several longitudinal metabolomics studies have been conducted in individuals with normal estimated glomerular filtration rate (eGFR) at baseline, disease progression among individuals with established chronic kidney disease (CKD) has not been rigorously examined. METHODS We performed a nested case-control study of rapid CKD progression in the Chronic Renal Insufficiency Cohort Study, profiling baseline plasma from 200 individuals each with eGFR slope <-3 ml/min/1.73 m2/year (cases) or between -1 and +1 ml/min/1.73 m2/year (controls), matched on baseline eGFR and proteinuria. To directly assess how the kidney modulates circulating metabolites, we profiled plasma from the aorta and renal vein of 25 hospital-based individuals. RESULTS At baseline, cases and controls had a mean eGFR of 41.7 ± 13.3 and 45.0 ± 14.5 ml/min/1.73 m2, respectively. Ten plasma metabolites were nominally associated with CKD progression in logistic regression models adjusted for age, sex, race/ethnicity, hypertension, systolic and diastolic blood pressure, diabetes, eGFR and proteinuria; no metabolite achieved the Bonferroni-adjusted significance threshold (p < 0.0003). In a cross-sectional analysis, all 6 of the metabolites that were higher in cases than controls were significantly associated with eGFR at baseline. By contrast, threonine, methionine and arginine were lower in cases than in controls and had no association with baseline eGFR. Furthermore, in the hospital-based cohort that underwent renal arteriovenous sampling, these 3 metabolites were net released from the kidney. Combining these metabolites into a panel of markers further strengthened their association with CKD progression. CONCLUSION Our results motivate interest in arginine, methionine and threonine as potential indicators of renal metabolic function and markers of renal prognosis.
Collapse
Affiliation(s)
- Eugene P Rhee
- Metabolite Profiling, Broad Institute, Cambridge, Mass., USA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Chouchani ET, Kazak L, Jedrychowski MP, Lu GZ, Erickson BK, Szpyt J, Pierce KA, Laznik-Bogoslavski D, Vetrivelan R, Clish CB, Robinson AJ, Gygi SP, Spiegelman BM. Mitochondrial ROS regulate thermogenic energy expenditure and sulfenylation of UCP1. Nature 2016; 532:112-6. [PMID: 27027295 PMCID: PMC5549630 DOI: 10.1038/nature17399] [Citation(s) in RCA: 311] [Impact Index Per Article: 38.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2015] [Accepted: 02/04/2016] [Indexed: 02/06/2023]
Abstract
Brown adipose tissue (BAT) can dissipate chemical energy as heat through thermogenic respiration, which requires uncoupling protein 1 (UCP1)1,2. Thermogenesis from BAT and beige adipose can combat obesity and diabetes3, encouraging investigation of factors that control UCP1-dependent respiration in vivo. Herein we show that acutely activated BAT thermogenesis is defined by a substantial increase in mitochondrial reactive oxygen species (ROS) levels. Remarkably, this process supports in vivo BAT thermogenesis, as pharmacological depletion of mitochondrial ROS results in hypothermia upon cold exposure, and inhibits UCP1-dependent increases in whole body energy expenditure. We further establish that thermogenic ROS alter BAT cysteine thiol redox status to drive increased respiration, and Cys253 of UCP1 is a key target. UCP1 Cys253 is sulfenylated during thermogenesis, while mutation of this site desensitizes the purine nucleotide inhibited state of the carrier to adrenergic activation and uncoupling. These studies identify BAT mitochondrial ROS induction as a mechanism that drives UCP1-dependent thermogenesis and whole body energy expenditure, which opens the way to develop improved therapeutic strategies for combating metabolic disorders.
Collapse
Affiliation(s)
- Edward T Chouchani
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.,Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Lawrence Kazak
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.,Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Mark P Jedrychowski
- Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Gina Z Lu
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.,Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Brian K Erickson
- Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - John Szpyt
- Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Kerry A Pierce
- Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA
| | | | | | - Clary B Clish
- Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA
| | - Alan J Robinson
- MRC Mitochondrial Biology Unit, Hills Road, Cambridge CB2 0XY, UK
| | - Steve P Gygi
- Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
| | - Bruce M Spiegelman
- Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA.,Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA
| |
Collapse
|
21
|
Cheng S, Larson MG, McCabe EL, Murabito JM, Rhee EP, Ho JE, Jacques PF, Ghorbani A, Magnusson M, Souza AL, Deik AA, Pierce KA, Bullock K, O'Donnell CJ, Melander O, Clish CB, Vasan RS, Gerszten RE, Wang TJ. Distinct metabolomic signatures are associated with longevity in humans. Nat Commun 2015; 6:6791. [PMID: 25864806 PMCID: PMC4396657 DOI: 10.1038/ncomms7791] [Citation(s) in RCA: 92] [Impact Index Per Article: 10.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2014] [Accepted: 02/27/2015] [Indexed: 01/07/2023] Open
Abstract
Alterations in metabolism influence lifespan in experimental models, but data in humans are lacking. Here we use liquid chromatography/mass spectrometry to quantify 217 plasma metabolites and examine their relation to longevity in a large cohort of men and women. In 647 individuals followed for up to 20 years, higher concentrations of the citric acid cycle intermediate, isocitrate, and the bile acid, taurocholate, are associated with lower odds of longevity, defined as attaining 80 years of age. In a larger cohort of 2,327 individuals with metabolite data available, higher concentrations of isocitrate but not taurocholate are also associated with worse cardiovascular health at baseline, as well as risk of future cardiovascular disease and death. None of the metabolites identified are associated with cancer risk. Our findings suggest that some, but not all, metabolic pathways to human longevity are dependent on modifying risk for the two most common causes of death.
Collapse
Affiliation(s)
- Susan Cheng
- Framingham Heart Study of the National Heart, Lung and Blood Institute and Boston University School of Medicine, Framingham, MA (SC, MGL, JMM, JEH, CJO, RSV, TJW); Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SC); Department of Mathematics and Statistics, Boston University, Boston, MA (MGL); Department of Biostatistics, Boston University School of Public Health, Boston, MA (ELM); Cardiology Division (JEH, AG, CJO, REG), Cardiovascular Research Center (REG), and Renal Division (EPR), Massachusetts General Hospital, Harvard Medical School, Boston, MA; General Internal Medicine (JMM), Cardiology (JEH, RSV), and Preventive Medicine (RSV), Department of Medicine, Boston University School of Medicine, Boston, MA; Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (PFJ); Department of Clinical Sciences, Lund University, Malmö (MM, OM); Broad Institute of MIT and Harvard, Cambridge, MA (ALS, AAD, KAP, KB, CBC, REG); National Heart, Lung & Blood Institute Division of Intramural Research, Bethesda, MD (CJO); and, Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN (TJW)
| | - Martin G Larson
- Framingham Heart Study of the National Heart, Lung and Blood Institute and Boston University School of Medicine, Framingham, MA (SC, MGL, JMM, JEH, CJO, RSV, TJW); Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SC); Department of Mathematics and Statistics, Boston University, Boston, MA (MGL); Department of Biostatistics, Boston University School of Public Health, Boston, MA (ELM); Cardiology Division (JEH, AG, CJO, REG), Cardiovascular Research Center (REG), and Renal Division (EPR), Massachusetts General Hospital, Harvard Medical School, Boston, MA; General Internal Medicine (JMM), Cardiology (JEH, RSV), and Preventive Medicine (RSV), Department of Medicine, Boston University School of Medicine, Boston, MA; Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (PFJ); Department of Clinical Sciences, Lund University, Malmö (MM, OM); Broad Institute of MIT and Harvard, Cambridge, MA (ALS, AAD, KAP, KB, CBC, REG); National Heart, Lung & Blood Institute Division of Intramural Research, Bethesda, MD (CJO); and, Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN (TJW)
| | - Elizabeth L McCabe
- Framingham Heart Study of the National Heart, Lung and Blood Institute and Boston University School of Medicine, Framingham, MA (SC, MGL, JMM, JEH, CJO, RSV, TJW); Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SC); Department of Mathematics and Statistics, Boston University, Boston, MA (MGL); Department of Biostatistics, Boston University School of Public Health, Boston, MA (ELM); Cardiology Division (JEH, AG, CJO, REG), Cardiovascular Research Center (REG), and Renal Division (EPR), Massachusetts General Hospital, Harvard Medical School, Boston, MA; General Internal Medicine (JMM), Cardiology (JEH, RSV), and Preventive Medicine (RSV), Department of Medicine, Boston University School of Medicine, Boston, MA; Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (PFJ); Department of Clinical Sciences, Lund University, Malmö (MM, OM); Broad Institute of MIT and Harvard, Cambridge, MA (ALS, AAD, KAP, KB, CBC, REG); National Heart, Lung & Blood Institute Division of Intramural Research, Bethesda, MD (CJO); and, Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN (TJW)
| | - Joanne M Murabito
- Framingham Heart Study of the National Heart, Lung and Blood Institute and Boston University School of Medicine, Framingham, MA (SC, MGL, JMM, JEH, CJO, RSV, TJW); Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SC); Department of Mathematics and Statistics, Boston University, Boston, MA (MGL); Department of Biostatistics, Boston University School of Public Health, Boston, MA (ELM); Cardiology Division (JEH, AG, CJO, REG), Cardiovascular Research Center (REG), and Renal Division (EPR), Massachusetts General Hospital, Harvard Medical School, Boston, MA; General Internal Medicine (JMM), Cardiology (JEH, RSV), and Preventive Medicine (RSV), Department of Medicine, Boston University School of Medicine, Boston, MA; Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (PFJ); Department of Clinical Sciences, Lund University, Malmö (MM, OM); Broad Institute of MIT and Harvard, Cambridge, MA (ALS, AAD, KAP, KB, CBC, REG); National Heart, Lung & Blood Institute Division of Intramural Research, Bethesda, MD (CJO); and, Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN (TJW)
| | - Eugene P Rhee
- Framingham Heart Study of the National Heart, Lung and Blood Institute and Boston University School of Medicine, Framingham, MA (SC, MGL, JMM, JEH, CJO, RSV, TJW); Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SC); Department of Mathematics and Statistics, Boston University, Boston, MA (MGL); Department of Biostatistics, Boston University School of Public Health, Boston, MA (ELM); Cardiology Division (JEH, AG, CJO, REG), Cardiovascular Research Center (REG), and Renal Division (EPR), Massachusetts General Hospital, Harvard Medical School, Boston, MA; General Internal Medicine (JMM), Cardiology (JEH, RSV), and Preventive Medicine (RSV), Department of Medicine, Boston University School of Medicine, Boston, MA; Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (PFJ); Department of Clinical Sciences, Lund University, Malmö (MM, OM); Broad Institute of MIT and Harvard, Cambridge, MA (ALS, AAD, KAP, KB, CBC, REG); National Heart, Lung & Blood Institute Division of Intramural Research, Bethesda, MD (CJO); and, Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN (TJW)
| | - Jennifer E Ho
- Framingham Heart Study of the National Heart, Lung and Blood Institute and Boston University School of Medicine, Framingham, MA (SC, MGL, JMM, JEH, CJO, RSV, TJW); Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SC); Department of Mathematics and Statistics, Boston University, Boston, MA (MGL); Department of Biostatistics, Boston University School of Public Health, Boston, MA (ELM); Cardiology Division (JEH, AG, CJO, REG), Cardiovascular Research Center (REG), and Renal Division (EPR), Massachusetts General Hospital, Harvard Medical School, Boston, MA; General Internal Medicine (JMM), Cardiology (JEH, RSV), and Preventive Medicine (RSV), Department of Medicine, Boston University School of Medicine, Boston, MA; Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (PFJ); Department of Clinical Sciences, Lund University, Malmö (MM, OM); Broad Institute of MIT and Harvard, Cambridge, MA (ALS, AAD, KAP, KB, CBC, REG); National Heart, Lung & Blood Institute Division of Intramural Research, Bethesda, MD (CJO); and, Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN (TJW)
| | - Paul F Jacques
- Framingham Heart Study of the National Heart, Lung and Blood Institute and Boston University School of Medicine, Framingham, MA (SC, MGL, JMM, JEH, CJO, RSV, TJW); Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SC); Department of Mathematics and Statistics, Boston University, Boston, MA (MGL); Department of Biostatistics, Boston University School of Public Health, Boston, MA (ELM); Cardiology Division (JEH, AG, CJO, REG), Cardiovascular Research Center (REG), and Renal Division (EPR), Massachusetts General Hospital, Harvard Medical School, Boston, MA; General Internal Medicine (JMM), Cardiology (JEH, RSV), and Preventive Medicine (RSV), Department of Medicine, Boston University School of Medicine, Boston, MA; Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (PFJ); Department of Clinical Sciences, Lund University, Malmö (MM, OM); Broad Institute of MIT and Harvard, Cambridge, MA (ALS, AAD, KAP, KB, CBC, REG); National Heart, Lung & Blood Institute Division of Intramural Research, Bethesda, MD (CJO); and, Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN (TJW)
| | - Anahita Ghorbani
- Framingham Heart Study of the National Heart, Lung and Blood Institute and Boston University School of Medicine, Framingham, MA (SC, MGL, JMM, JEH, CJO, RSV, TJW); Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SC); Department of Mathematics and Statistics, Boston University, Boston, MA (MGL); Department of Biostatistics, Boston University School of Public Health, Boston, MA (ELM); Cardiology Division (JEH, AG, CJO, REG), Cardiovascular Research Center (REG), and Renal Division (EPR), Massachusetts General Hospital, Harvard Medical School, Boston, MA; General Internal Medicine (JMM), Cardiology (JEH, RSV), and Preventive Medicine (RSV), Department of Medicine, Boston University School of Medicine, Boston, MA; Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (PFJ); Department of Clinical Sciences, Lund University, Malmö (MM, OM); Broad Institute of MIT and Harvard, Cambridge, MA (ALS, AAD, KAP, KB, CBC, REG); National Heart, Lung & Blood Institute Division of Intramural Research, Bethesda, MD (CJO); and, Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN (TJW)
| | - Martin Magnusson
- Framingham Heart Study of the National Heart, Lung and Blood Institute and Boston University School of Medicine, Framingham, MA (SC, MGL, JMM, JEH, CJO, RSV, TJW); Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SC); Department of Mathematics and Statistics, Boston University, Boston, MA (MGL); Department of Biostatistics, Boston University School of Public Health, Boston, MA (ELM); Cardiology Division (JEH, AG, CJO, REG), Cardiovascular Research Center (REG), and Renal Division (EPR), Massachusetts General Hospital, Harvard Medical School, Boston, MA; General Internal Medicine (JMM), Cardiology (JEH, RSV), and Preventive Medicine (RSV), Department of Medicine, Boston University School of Medicine, Boston, MA; Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (PFJ); Department of Clinical Sciences, Lund University, Malmö (MM, OM); Broad Institute of MIT and Harvard, Cambridge, MA (ALS, AAD, KAP, KB, CBC, REG); National Heart, Lung & Blood Institute Division of Intramural Research, Bethesda, MD (CJO); and, Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN (TJW)
| | - Amanda L Souza
- Framingham Heart Study of the National Heart, Lung and Blood Institute and Boston University School of Medicine, Framingham, MA (SC, MGL, JMM, JEH, CJO, RSV, TJW); Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SC); Department of Mathematics and Statistics, Boston University, Boston, MA (MGL); Department of Biostatistics, Boston University School of Public Health, Boston, MA (ELM); Cardiology Division (JEH, AG, CJO, REG), Cardiovascular Research Center (REG), and Renal Division (EPR), Massachusetts General Hospital, Harvard Medical School, Boston, MA; General Internal Medicine (JMM), Cardiology (JEH, RSV), and Preventive Medicine (RSV), Department of Medicine, Boston University School of Medicine, Boston, MA; Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (PFJ); Department of Clinical Sciences, Lund University, Malmö (MM, OM); Broad Institute of MIT and Harvard, Cambridge, MA (ALS, AAD, KAP, KB, CBC, REG); National Heart, Lung & Blood Institute Division of Intramural Research, Bethesda, MD (CJO); and, Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN (TJW)
| | - Amy A Deik
- Framingham Heart Study of the National Heart, Lung and Blood Institute and Boston University School of Medicine, Framingham, MA (SC, MGL, JMM, JEH, CJO, RSV, TJW); Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SC); Department of Mathematics and Statistics, Boston University, Boston, MA (MGL); Department of Biostatistics, Boston University School of Public Health, Boston, MA (ELM); Cardiology Division (JEH, AG, CJO, REG), Cardiovascular Research Center (REG), and Renal Division (EPR), Massachusetts General Hospital, Harvard Medical School, Boston, MA; General Internal Medicine (JMM), Cardiology (JEH, RSV), and Preventive Medicine (RSV), Department of Medicine, Boston University School of Medicine, Boston, MA; Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (PFJ); Department of Clinical Sciences, Lund University, Malmö (MM, OM); Broad Institute of MIT and Harvard, Cambridge, MA (ALS, AAD, KAP, KB, CBC, REG); National Heart, Lung & Blood Institute Division of Intramural Research, Bethesda, MD (CJO); and, Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN (TJW)
| | - Kerry A Pierce
- Framingham Heart Study of the National Heart, Lung and Blood Institute and Boston University School of Medicine, Framingham, MA (SC, MGL, JMM, JEH, CJO, RSV, TJW); Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SC); Department of Mathematics and Statistics, Boston University, Boston, MA (MGL); Department of Biostatistics, Boston University School of Public Health, Boston, MA (ELM); Cardiology Division (JEH, AG, CJO, REG), Cardiovascular Research Center (REG), and Renal Division (EPR), Massachusetts General Hospital, Harvard Medical School, Boston, MA; General Internal Medicine (JMM), Cardiology (JEH, RSV), and Preventive Medicine (RSV), Department of Medicine, Boston University School of Medicine, Boston, MA; Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (PFJ); Department of Clinical Sciences, Lund University, Malmö (MM, OM); Broad Institute of MIT and Harvard, Cambridge, MA (ALS, AAD, KAP, KB, CBC, REG); National Heart, Lung & Blood Institute Division of Intramural Research, Bethesda, MD (CJO); and, Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN (TJW)
| | - Kevin Bullock
- Framingham Heart Study of the National Heart, Lung and Blood Institute and Boston University School of Medicine, Framingham, MA (SC, MGL, JMM, JEH, CJO, RSV, TJW); Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SC); Department of Mathematics and Statistics, Boston University, Boston, MA (MGL); Department of Biostatistics, Boston University School of Public Health, Boston, MA (ELM); Cardiology Division (JEH, AG, CJO, REG), Cardiovascular Research Center (REG), and Renal Division (EPR), Massachusetts General Hospital, Harvard Medical School, Boston, MA; General Internal Medicine (JMM), Cardiology (JEH, RSV), and Preventive Medicine (RSV), Department of Medicine, Boston University School of Medicine, Boston, MA; Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (PFJ); Department of Clinical Sciences, Lund University, Malmö (MM, OM); Broad Institute of MIT and Harvard, Cambridge, MA (ALS, AAD, KAP, KB, CBC, REG); National Heart, Lung & Blood Institute Division of Intramural Research, Bethesda, MD (CJO); and, Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN (TJW)
| | - Christopher J O'Donnell
- Framingham Heart Study of the National Heart, Lung and Blood Institute and Boston University School of Medicine, Framingham, MA (SC, MGL, JMM, JEH, CJO, RSV, TJW); Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SC); Department of Mathematics and Statistics, Boston University, Boston, MA (MGL); Department of Biostatistics, Boston University School of Public Health, Boston, MA (ELM); Cardiology Division (JEH, AG, CJO, REG), Cardiovascular Research Center (REG), and Renal Division (EPR), Massachusetts General Hospital, Harvard Medical School, Boston, MA; General Internal Medicine (JMM), Cardiology (JEH, RSV), and Preventive Medicine (RSV), Department of Medicine, Boston University School of Medicine, Boston, MA; Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (PFJ); Department of Clinical Sciences, Lund University, Malmö (MM, OM); Broad Institute of MIT and Harvard, Cambridge, MA (ALS, AAD, KAP, KB, CBC, REG); National Heart, Lung & Blood Institute Division of Intramural Research, Bethesda, MD (CJO); and, Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN (TJW)
| | - Olle Melander
- Framingham Heart Study of the National Heart, Lung and Blood Institute and Boston University School of Medicine, Framingham, MA (SC, MGL, JMM, JEH, CJO, RSV, TJW); Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SC); Department of Mathematics and Statistics, Boston University, Boston, MA (MGL); Department of Biostatistics, Boston University School of Public Health, Boston, MA (ELM); Cardiology Division (JEH, AG, CJO, REG), Cardiovascular Research Center (REG), and Renal Division (EPR), Massachusetts General Hospital, Harvard Medical School, Boston, MA; General Internal Medicine (JMM), Cardiology (JEH, RSV), and Preventive Medicine (RSV), Department of Medicine, Boston University School of Medicine, Boston, MA; Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (PFJ); Department of Clinical Sciences, Lund University, Malmö (MM, OM); Broad Institute of MIT and Harvard, Cambridge, MA (ALS, AAD, KAP, KB, CBC, REG); National Heart, Lung & Blood Institute Division of Intramural Research, Bethesda, MD (CJO); and, Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN (TJW)
| | - Clary B Clish
- Framingham Heart Study of the National Heart, Lung and Blood Institute and Boston University School of Medicine, Framingham, MA (SC, MGL, JMM, JEH, CJO, RSV, TJW); Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SC); Department of Mathematics and Statistics, Boston University, Boston, MA (MGL); Department of Biostatistics, Boston University School of Public Health, Boston, MA (ELM); Cardiology Division (JEH, AG, CJO, REG), Cardiovascular Research Center (REG), and Renal Division (EPR), Massachusetts General Hospital, Harvard Medical School, Boston, MA; General Internal Medicine (JMM), Cardiology (JEH, RSV), and Preventive Medicine (RSV), Department of Medicine, Boston University School of Medicine, Boston, MA; Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (PFJ); Department of Clinical Sciences, Lund University, Malmö (MM, OM); Broad Institute of MIT and Harvard, Cambridge, MA (ALS, AAD, KAP, KB, CBC, REG); National Heart, Lung & Blood Institute Division of Intramural Research, Bethesda, MD (CJO); and, Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN (TJW)
| | - Ramachandran S Vasan
- Framingham Heart Study of the National Heart, Lung and Blood Institute and Boston University School of Medicine, Framingham, MA (SC, MGL, JMM, JEH, CJO, RSV, TJW); Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SC); Department of Mathematics and Statistics, Boston University, Boston, MA (MGL); Department of Biostatistics, Boston University School of Public Health, Boston, MA (ELM); Cardiology Division (JEH, AG, CJO, REG), Cardiovascular Research Center (REG), and Renal Division (EPR), Massachusetts General Hospital, Harvard Medical School, Boston, MA; General Internal Medicine (JMM), Cardiology (JEH, RSV), and Preventive Medicine (RSV), Department of Medicine, Boston University School of Medicine, Boston, MA; Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (PFJ); Department of Clinical Sciences, Lund University, Malmö (MM, OM); Broad Institute of MIT and Harvard, Cambridge, MA (ALS, AAD, KAP, KB, CBC, REG); National Heart, Lung & Blood Institute Division of Intramural Research, Bethesda, MD (CJO); and, Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN (TJW)
| | - Robert E Gerszten
- Framingham Heart Study of the National Heart, Lung and Blood Institute and Boston University School of Medicine, Framingham, MA (SC, MGL, JMM, JEH, CJO, RSV, TJW); Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SC); Department of Mathematics and Statistics, Boston University, Boston, MA (MGL); Department of Biostatistics, Boston University School of Public Health, Boston, MA (ELM); Cardiology Division (JEH, AG, CJO, REG), Cardiovascular Research Center (REG), and Renal Division (EPR), Massachusetts General Hospital, Harvard Medical School, Boston, MA; General Internal Medicine (JMM), Cardiology (JEH, RSV), and Preventive Medicine (RSV), Department of Medicine, Boston University School of Medicine, Boston, MA; Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (PFJ); Department of Clinical Sciences, Lund University, Malmö (MM, OM); Broad Institute of MIT and Harvard, Cambridge, MA (ALS, AAD, KAP, KB, CBC, REG); National Heart, Lung & Blood Institute Division of Intramural Research, Bethesda, MD (CJO); and, Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN (TJW)
| | - Thomas J Wang
- Framingham Heart Study of the National Heart, Lung and Blood Institute and Boston University School of Medicine, Framingham, MA (SC, MGL, JMM, JEH, CJO, RSV, TJW); Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (SC); Department of Mathematics and Statistics, Boston University, Boston, MA (MGL); Department of Biostatistics, Boston University School of Public Health, Boston, MA (ELM); Cardiology Division (JEH, AG, CJO, REG), Cardiovascular Research Center (REG), and Renal Division (EPR), Massachusetts General Hospital, Harvard Medical School, Boston, MA; General Internal Medicine (JMM), Cardiology (JEH, RSV), and Preventive Medicine (RSV), Department of Medicine, Boston University School of Medicine, Boston, MA; Jean Mayer US Department of Agriculture Human Nutrition Research Center on Aging, Tufts University, Boston, MA (PFJ); Department of Clinical Sciences, Lund University, Malmö (MM, OM); Broad Institute of MIT and Harvard, Cambridge, MA (ALS, AAD, KAP, KB, CBC, REG); National Heart, Lung & Blood Institute Division of Intramural Research, Bethesda, MD (CJO); and, Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN (TJW)
| |
Collapse
|
22
|
Lennerz BS, Vafai SB, Delaney NF, Clish CB, Deik AA, Pierce KA, Ludwig DS, Mootha VK. Effects of sodium benzoate, a widely used food preservative, on glucose homeostasis and metabolic profiles in humans. Mol Genet Metab 2015; 114:73-9. [PMID: 25497115 PMCID: PMC4289147 DOI: 10.1016/j.ymgme.2014.11.010] [Citation(s) in RCA: 69] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/16/2014] [Revised: 11/11/2014] [Accepted: 11/11/2014] [Indexed: 11/25/2022]
Abstract
Sodium benzoate is a widely used preservative found in many foods and soft drinks. It is metabolized within mitochondria to produce hippurate, which is then cleared by the kidneys. We previously reported that ingestion of sodium benzoate at the generally regarded as safe (GRAS) dose leads to a robust excursion in the plasma hippurate level [1]. Since previous reports demonstrated adverse effects of benzoate and hippurate on glucose homeostasis in cells and in animal models, we hypothesized that benzoate might represent a widespread and underappreciated diabetogenic dietary exposure in humans. Here, we evaluated whether acute exposure to GRAS levels of sodium benzoate alters insulin and glucose homeostasis through a randomized, controlled, cross-over study of 14 overweight subjects. Serial blood samples were collected following an oral glucose challenge, in the presence or absence of sodium benzoate. Outcome measurements included glucose, insulin, glucagon, as well as temporal mass spectrometry-based metabolic profiles. We did not find a statistically significant effect of an acute oral exposure to sodium benzoate on glucose homeostasis. Of the 146 metabolites targeted, four changed significantly in response to benzoate, including the expected rise in benzoate and hippurate. In addition, anthranilic acid, a tryptophan metabolite, exhibited a robust rise, while acetylglycine dropped. Although our study shows that GRAS doses of benzoate do not have an acute, adverse effect on glucose homeostasis, future studies will be necessary to explore the metabolic impact of chronic benzoate exposure.
Collapse
Affiliation(s)
- Belinda S Lennerz
- Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, USA.
| | - Scott B Vafai
- Massachusetts General Hospital, Boston MA 02114, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
| | | | - Clary B Clish
- Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
| | - Amy A Deik
- Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
| | - Kerry A Pierce
- Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
| | - David S Ludwig
- Boston Children's Hospital, 300 Longwood Avenue, Boston, MA 02115, USA.
| | - Vamsi K Mootha
- Massachusetts General Hospital, Boston MA 02114, USA; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
| |
Collapse
|
23
|
Avanesov AS, Ma S, Pierce KA, Yim SH, Lee BC, Clish CB, Gladyshev VN. Age- and diet-associated metabolome remodeling characterizes the aging process driven by damage accumulation. eLife 2014; 3:e02077. [PMID: 24843015 PMCID: PMC4003482 DOI: 10.7554/elife.02077] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Aging is thought to be associated with increased molecular damage, but representative markers vary across conditions and organisms, making it difficult to assess properties of cumulative damage throughout lifespan. We used nontargeted metabolite profiling to follow age-associated trajectories of >15,000 metabolites in Drosophila subjected to control and lifespan-extending diets. We find that aging is associated with increased metabolite diversity and low-abundance molecules, suggesting they include cumulative damage. Remarkably, the number of detected compounds leveled-off in late-life, and this pattern associated with survivorship. Fourteen percent of metabolites showed age-associated changes, which decelerated in late-life and long-lived flies. In contrast, known metabolites changed in abundance similarly to nontargeted metabolites and transcripts, but did not increase in diversity. Targeted profiling also revealed slower metabolism and accumulation of lifespan-limiting molecules. Thus, aging is characterized by gradual metabolome remodeling, and condition- and advanced age-associated deceleration of this remodeling is linked to mortality and molecular damage.DOI: http://dx.doi.org/10.7554/eLife.02077.001.
Collapse
Affiliation(s)
- Andrei S Avanesov
- Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, United States
| | - Siming Ma
- Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, United States
| | | | - Sun Hee Yim
- Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, United States
| | - Byung Cheon Lee
- Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, United States
| | | | - Vadim N Gladyshev
- Division of Genetics, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, United States Broad Institute, Cambridge, United States
| |
Collapse
|
24
|
Wang TJ, Ngo D, Psychogios N, Dejam A, Larson MG, Vasan RS, Ghorbani A, O'Sullivan J, Cheng S, Rhee EP, Sinha S, McCabe E, Fox CS, O'Donnell CJ, Ho JE, Florez JC, Magnusson M, Pierce KA, Souza AL, Yu Y, Carter C, Light PE, Melander O, Clish CB, Gerszten RE. 2-Aminoadipic acid is a biomarker for diabetes risk. J Clin Invest 2013; 123:4309-17. [PMID: 24091325 DOI: 10.1172/jci64801] [Citation(s) in RCA: 325] [Impact Index Per Article: 29.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2013] [Accepted: 07/20/2013] [Indexed: 12/20/2022] Open
Abstract
Improvements in metabolite-profiling techniques are providing increased breadth of coverage of the human metabolome and may highlight biomarkers and pathways in common diseases such as diabetes. Using a metabolomics platform that analyzes intermediary organic acids, purines, pyrimidines, and other compounds, we performed a nested case-control study of 188 individuals who developed diabetes and 188 propensity-matched controls from 2,422 normoglycemic participants followed for 12 years in the Framingham Heart Study. The metabolite 2-aminoadipic acid (2-AAA) was most strongly associated with the risk of developing diabetes. Individuals with 2-AAA concentrations in the top quartile had greater than a 4-fold risk of developing diabetes. Levels of 2-AAA were not well correlated with other metabolite biomarkers of diabetes, such as branched chain amino acids and aromatic amino acids, suggesting they report on a distinct pathophysiological pathway. In experimental studies, administration of 2-AAA lowered fasting plasma glucose levels in mice fed both standard chow and high-fat diets. Further, 2-AAA treatment enhanced insulin secretion from a pancreatic β cell line as well as murine and human islets. These data highlight a metabolite not previously associated with diabetes risk that is increased up to 12 years before the onset of overt disease. Our findings suggest that 2-AAA is a marker of diabetes risk and a potential modulator of glucose homeostasis in humans.
Collapse
|
25
|
Rhee EP, Ho JE, Chen MH, Shen D, Cheng S, Larson MG, Ghorbani A, Shi X, Helenius IT, O'Donnell CJ, Souza AL, Deik A, Pierce KA, Bullock K, Walford GA, Vasan RS, Florez JC, Clish C, Yeh JRJ, Wang TJ, Gerszten RE. A genome-wide association study of the human metabolome in a community-based cohort. Cell Metab 2013; 18:130-43. [PMID: 23823483 PMCID: PMC3973158 DOI: 10.1016/j.cmet.2013.06.013] [Citation(s) in RCA: 229] [Impact Index Per Article: 20.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2013] [Revised: 04/10/2013] [Accepted: 06/18/2013] [Indexed: 12/23/2022]
Abstract
Because metabolites are hypothesized to play key roles as markers and effectors of cardiometabolic diseases, recent studies have sought to annotate the genetic determinants of circulating metabolite levels. We report a genome-wide association study (GWAS) of 217 plasma metabolites, including >100 not measured in prior GWAS, in 2076 participants of the Framingham Heart Study (FHS). For the majority of analytes, we find that estimated heritability explains >20% of interindividual variation, and that variation attributable to heritable factors is greater than that attributable to clinical factors. Further, we identify 31 genetic loci associated with plasma metabolites, including 23 that have not previously been reported. Importantly, we include GWAS results for all surveyed metabolites and demonstrate how this information highlights a role for AGXT2 in cholesterol ester and triacylglycerol metabolism. Thus, our study outlines the relative contributions of inherited and clinical factors on the plasma metabolome and provides a resource for metabolism research.
Collapse
Affiliation(s)
- Eugene P Rhee
- Nephrology Division, Massachusetts General Hospital, Boston, MA 02114, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
26
|
Pierce KA, Paddock CD, Sumner JW, Nicholson WL. Pathogen prevalence and blood meal identification in Amblyomma ticks as a means of reservoir host determination for ehrlichial pathogens. Clin Microbiol Infect 2009; 15 Suppl 2:37-8. [PMID: 19793129 DOI: 10.1111/j.1469-0691.2008.02166.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- K A Pierce
- Rickettsial Zoonoses Branch, Division of Viral and Rickettsial Diseases, National Center for Zoonotic, Vector-borne, and Enteric Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
| | | | | | | |
Collapse
|
27
|
D'Eon TM, Pierce KA, Roix JJ, Tyler A, Chen H, Teixeira SR. The role of adipocyte insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids. Diabetes 2008; 57:1262-8. [PMID: 18276766 DOI: 10.2337/db07-1186] [Citation(s) in RCA: 81] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
OBJECTIVE Obesity is associated with an overactive endocannabinoid (EC) system. The mechanisms responsible for increased ECs in obese individuals are poorly understood. Therefore, we examined the role of adipocyte insulin resistance in intracellular EC metabolism. METHODS We used 3T3-L1 adipocytes and diet-induced obese (DIO) mice to examine the role of obesity and insulin resistance in the regulation and/or dysregulation of intracellular ECs. RESULTS For the first time, we provide evidence that insulin is a major regulator of EC metabolism. Insulin treatment reduced intracellular ECs (2-arachidonylglycerol [2-AG] and anandamide [AEA]) in 3T3-L1 adipocytes. This corresponded with insulin-sensitive expression changes in enzymes of EC metabolism. In insulin-resistant adipocytes, patterns of insulin-induced enzyme expression were disturbed in a manner consistent with elevated EC synthesis and reduced EC degradation. Expression profiling of adipocytes from DIO mice largely recapitulated in vitro changes, suggesting that insulin resistance affects the EC system in vivo. In mice, expression changes of EC synthesis and degradation enzymes were accompanied by increased plasma EC concentrations (2-AG and AEA) and elevated adipose tissue 2-AG. CONCLUSIONS Our findings suggest that insulin-resistant adipocytes fail to regulate EC metabolism and decrease intracellular EC levels in response to insulin stimulation. These novel observations offer a mechanism whereby obese insulin-resistant individuals exhibit increased concentrations of ECs.
Collapse
Affiliation(s)
- Tara M D'Eon
- Metabolism Medical Team, Sanofi-Aventis, One Onslow Street, Guildford, Surrey, UK. tara.d'
| | | | | | | | | | | |
Collapse
|
28
|
Wu X, Ranganathan V, Weisman DS, Heine WF, Ciccone DN, O'Neill TB, Crick KE, Pierce KA, Lane WS, Rathbun G, Livingston DM, Weaver DT. ATM phosphorylation of Nijmegen breakage syndrome protein is required in a DNA damage response. Nature 2000; 405:477-82. [PMID: 10839545 DOI: 10.1038/35013089] [Citation(s) in RCA: 316] [Impact Index Per Article: 13.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Nijmegen breakage syndrome (NBS) is characterized by extreme radiation sensitivity, chromosomal instability and cancer. The phenotypes are similar to those of ataxia telangiectasia mutated (ATM) disease, where there is a deficiency in a protein kinase that is activated by DNA damage, indicating that the Nbs and Atm proteins may participate in common pathways. Here we report that Nbs is specifically phosphorylated in response to gamma-radiation, ultraviolet light and exposure to hydroxyurea. Phosphorylation of Nbs mediated by gamma-radiation, but not that induced by hydroxyurea or ultraviolet light, was markedly reduced in ATM cells. In vivo, Nbs was phosphorylated on many serine residues, of which S343, S397 and S615 were phosphorylated by Atm in vitro. At least two of these sites were underphosphorylated in ATM cells. Inactivation of these serines by mutation partially abrogated Atm-dependent phosphorylation. Reconstituting NBS cells with a mutant form of Nbs that cannot be phosphorylated at selected, ATM-dependent serine residues led to a specific reduction in clonogenic survival after gamma-radiation. Thus, phosphorylation of Nbs by Atm is critical for certain responses of human cells to DNA damage.
Collapse
Affiliation(s)
- X Wu
- Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Huddy DC, Johnson RL, Stone MH, Proulx CM, Pierce KA. Relationship between body image and percent body fat among male and female college students enrolled in an introductory 14-week weight-training course. Percept Mot Skills 1997; 85:1075-8. [PMID: 9399321 DOI: 10.2466/pms.1997.85.3.1075] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
Students (39 men and 27 women) from a southern university, who were enrolled in a 14-wk. introductory weight-training course, were administered a 20-item body-image questionnaire and subsequently underwent skinfold measurements to assess percent body fat. Mean scores were correlated with percent body fat. For men, women, and both sexes combined correlations were significant and inverse (rs = -.68, -.41, -.66, respectively). Body image as measured was inversely related to percent body fat among these college students. Researchers should examine how dietary and exercise-induced changes in adiposity (pre-post design) influence scores on body image.
Collapse
Affiliation(s)
- D C Huddy
- Department of Health, Leisure and Exercise Science, Appalachian State University, Boone, NC 28608, USA.
| | | | | | | | | |
Collapse
|
30
|
Pierce KA, Crain RM, Gholson B, Smither D, Rabinowitz FM. The Sources of Children's Errors during Nonisomorphic Analogical Transfer: Script Theory and Structure Mapping Theory. J Exp Child Psychol 1996; 62:102-30. [PMID: 8812035 DOI: 10.1006/jecp.1996.0024] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Nonisomorphic analogical transfer and procedural change were examined among 96 second and third graders. Hybrid versions of missionaries/cannibals and jealous husbands problems were used to provide three acquisition and two transfer tasks that were combined factorially, yielding six combinations. New constraints were added in transfer that altered the problem space and complicated the task. The amount of base modification that was required in transfer varied across conditions. In each condition the children were quite adept at applying their base to a nonisomorphic target at most choice points, despite the differences in problem descriptions, constraints, and problem spaces. For example, their response times on the first two moves in transfer were comparable to those obtained in isomorphic transfer. However, on specific moves that required base modification many of the children appeared confused, making two or more consecutive errors. The source of the errors seemed to stem from an inability of the children in some conditions to incorporate additional constraints into the structure of their existing base.
Collapse
|
31
|
Abstract
Assessed preschoolers' attitudes about orthopedically handicapped individuals with a standard picture-ranking task. Children generally exhibited a functionally related preference for nonhandicapped individuals. One month later, the same children were videotaped reading and playing basketball with a female adult in a wheelchair or in a chair. Preferences for a normal play partner during reading or during sports on the picture-ranking task did not relate to frequency of social interactions. Liking preference for a normal play partner, in conjunction with gender of the child, predicted frequency of social interactions during both tasks regardless of examiner's handicap status. Thus, the adoption of a negative bias had a general influence; any potential behavioral biases, as reflective of preference biases, were undifferentiated and unfocused in these preschoolers.
Collapse
Affiliation(s)
- R Cohen
- Department of Psychology, Memphis State University, Tennessee 38152
| | | | | |
Collapse
|
32
|
Abstract
Misapplied-size-constancy, assimilation, and contrast theories are discussed as explanations for the Wundt-Jastrow and Ponzo illusions. An experiment is reported that questions the need to include a contrast function in the assimilation theory of Pressey and Wilson to account for the Wundt-Jastrow illusion. Several directions for further research are proposed.
Collapse
Affiliation(s)
- D F Pick
- Department of Behavioral Sciences, Purdue University, Hammond, IN 46323
| | | |
Collapse
|
33
|
Abstract
The likelihood that males equivocate in their ratings of common fears was evaluated. A fear survey was given to 30 female and 26 male college students in a classroom setting. A second fear survey which contained duplicate items from the first was administered to the same students in a laboratory setting prior to watching videotaped scenes of fish, rats, mice and a shorter roller coaster ride. Before the second survey was given, the students received instructions which implied that their truthfulness could be independently evaluated through changes in their heart rate while they watched the videotape. Changes in the averaged fear ratings for the three high-fear items shown in the videotaped scenes were compared between males and females across the two survey conditions. Males' ratings of rats, mice, and roller coasters increased markedly from the first survey to the second, while fear ratings by females did not change. These results are consistent with the idea that the expression of fear by men is affected by conformation to the traditional male gender role.
Collapse
Affiliation(s)
- K A Pierce
- Department of Behavioral Sciences, Purdue University Calumet, Hammond, IN 46323
| | | |
Collapse
|